document incorporate reference specify portion registrant proxy statement file commission pursuant regulation connection registrant annual meeting stockholder hold incorporate reference iii report base closing price share june exclude share registrant common stock hold executive officer director stockholder ownership exceed registrant common stock outstanding june exclusion share construe indicate person possess power direct indirect direct cause direction management policy registrant person control common control registrantgilead sciences inc annual report table content item business item risk factor item b unresolved staff comment item property item legal proceeding item safety disclosure ii item market registrant common equity relate stockholder matter issuer purchase equity security item select financial datum item management discussion analysis financial condition result operation item quantitative qualitative disclosure market risk item financial statement supplementary datum item change disagreement accountant account financial disclosure item control procedure item b information iii item director executive officer corporate governance item executive compensation item security ownership certain beneficial owner management relate stockholder matter item certain relationship relate transaction director independence item principal accountant fee service iv item exhibit financial statement schedule item summary signature right trademark copyright trade name business include follow gilead gilead sciences ambisome cayston complera descovy emtriva epclusa eviplera genvoya harvoni hepsera letairis odefsey ranexa sovaldi stribild truvada tybost vemlidy viread vitekta volibris zydelig atripla register trademark bristolmyer squibb gilead sciences llc lexiscan register trademark astella llc macugen register trademark eyetech inc sustiva register trademark bristolmyers squibb pharma company tamiflu register trademark hoffmannla roche inc report include trademark service mark trade name companiesthis annual report include section entitle management discussion analysis financial condition result operation contain forwardlooke statement future event future result subject safe harbor create security act amend securities act securities exchange act amended exchange act word expect anticipate target goal project hope intend plan believe seek estimate continue variation word similar expression intend identify forwardlooke statement addition statement statement historical fact forward look statement include statement overall trend operate cost revenue trend liquidity capital need statement expectation belief future plan strategy anticipate event trend similar expression base forwardlooke statement current expectation future event statement guarantee future performance involve risk uncertainty assumption difficult predict actual result differ materially suggest forwardlooke statement reason include identify item head risk factor give risk uncertainty caution place undue reliance forwardlooke statement forwardlooke statement include report date hereof require federal security law rule regulation securities exchange commission sec undertake specifically decline obligation update statement publicly announce result revision forwardlooke statement distribution report result new information future event change assumption item business overview gilead sciences inc gilead incorporate delaware june researchbase biopharmaceutical company discover develop commercialize innovative medicine area unmet medical need new discovery investigational drug candidate strive transform simplify care people lifethreatene illness world operation country worldwide headquarters foster city california gileads primary area focus include human immunodeficiency virus hiv liver disease chronic hepatitis c virus hcv infection chronic hepatitis b virus hbv infection hematologyoncology cardiovascular inflammationrespiratory disease seek add exist portfolio product internal discovery clinical development program product acquisition inlicense strategy highlight past year continue bring bestinclass drug market advance standard care offering enhance mode delivery convenient treatment regimen improve resistance profile reduce effect great efficacy area hiv food drug administration fda european commission approve tenofovir alafenamide tafbase regimen odefsey emtricitabine mgrilpivirine mgtenofovir alafenamide mg treatment hiv infection certain patient descovy emtricitabine mgtenofovir alafenamide mg fixeddose combination treatment hiv infection liver disease area receive fda european commission approval epclusa sofosbuvir mgvelpatasvir mg alloral pangenotypic singletablet regimen treatment adult genotype chronic hcv infection epclusa singletablet regiman approve treatment patient hcv genotype need ribavirin receive fda approval vemlidy tenofovir alafenamide mg oncedaily treatment adult hbv infection compensate liver disease inflammationrespiratory area advance filgotinib jak inhibitor develop galapagos nv galapagos phase clinical trial potential treatment rheumatoid arthritis crohns disease ulcerative colitis end research development pipeline include active clinical study phase clinical trial addition advance treatment option therapeutic area enable access medication people need world continue expand access medicine low middleincome country pursue multiple strategy include enter collaboration government generic manufacturer regional business partner policy maker healthcare provider patient group public health entity today million people receive gilead hiv medicine low middleincome country enter partnership world health organization provide million funding drug donation year expand access diagnostic service treatment visceral leishmaniasis world seconddeadli parasitic infectious disease affect people annually resourcelimite country hiv goal ensure hiv patient choose singletablet regiman right singletablet regimen allow patient adhere fully suppressive course therapy easily consistently critical successful management disease hiv patient live long face additional health challenge experience newly diagnose patient motivate continue improve exist treatment option need efficacy improve longterm safety drive development program design study complete plan taf singletablet regimen seek address diverse need hiv patient worldwide taf novel target prodrug tenofovir demonstrate high antiviral efficacy similar dose onetenth viread tenofovir disoproxil fumarate tdf improvement surrogate laboratory marker renal bone safety compare tdf clinical trial combination antiretroviral agent launch tafbase singletablet regimen genvoya elvitegravir mgcobicistat mgemtricitabine mgtenofovir alafenamide mg odefsey singletablet regimen available treatment hiv odefsey currently small pill singletablet regimen treatment hiv descovy fixeddose combination treatment hiv represent important evolution hiv care new hiv treatment backbone approve fda decade addition evaluate bictegraviremtricitabinetaf phase study treatment hiv anticipate complete study quarter liver disease goal advance treatment option standard care hcv market approval sovaldi sofosbuvir mg compare prior standard care week duration treatment shorten week need peginterferon injection certain viral genotype population reduce eliminate completely harvoni ledipasvir mgsofosbuvir mg oncedaily singletablet regimen treatment hcv genotype infect patient prevalent genotype united states receive approval epclusa alloral pan genotypic singletablet regimen treatment adult genotype chronic hcv infection epclusa singletablet regiman approve treatment patient hcv genotype need ribavirin fourth quarter submit new drug application fda approval investigational oncedaily singletablet regiman contain sofosbuvir mg velpatasvir mg voxilaprevir mg sofvelvox treatment hcv product approve offer effective cure patient fail prior therapy highly effective regimen receive fda approval vemlidy oncedaily treatment adult hbv infection compensate liver disease evaluate selonsertib investigational smallmolecule inhibitor apoptosis signalregulating kinase ask treatment nonalcoholic steatohepatitis nash phase clinical trial base phase result intend evaluate selonsertib patient nash moderate severe fibrosis compound different mechanism currently phase study patient nash fibrosis gs fxr agonist gs acetylcoa carboxylase acc inhibitor pende demonstration single agent efficacy safety phase study plan initiate combination study agent hematologyoncology hematologyoncology area continue progress product candidate clinical trial idelalisib pik delta inhibitor phase clinical trial treatment patient relapse refractory chronic lymphocytic leukemia cll evaluate gs investigational antimmp antibody phase study treatment gastric cancer inflammationrespiratory close license collaboration agreement galapago clinicalstage biotechnology company base belgium development commercialization filgotinib jak inhibitor evaluate phase trial inflammatory disease indication rheumatoid arthritis crohns disease ulcerative colitis expect initiate phase clinical trial evaluate filgotinib combination gs syk inhibitor gs btk inhibitor potential treatment rheumatoid arthritis product hiv descovy oral formulation indicate combination antiretroviral agent treatment hiv infection adult pediatric patient year age old descovy fixeddose combination antiretroviral medication emtriva emtricitabine taf descovy approve fda european commission april odefsey oral formulation dose day treatment hiv infection certain patient odefsey fixeddose combination antiretroviral medication emtriva taf rilpivirine market janssen sciences ireland uc janssen janssen pharmaceutical companies johnson johnson odefsey represent small pill singletablet regimen treatment hiv odefsey approve fda march european commission june genvoya oral formulation dose day treatment hiv infection adult genvoya singletablet regimen treatment hiv fixeddose combination antiretroviral medicine vitekta elvitegravir tybost cobicistat emtriva taf stribild elvitegravircobicistatemtricitabinetdf oral formulation dose day treatment hiv infection treatmentnaive adult stribild singletablet regimen treatment hiv fixeddose combination antiretroviral medication vitekta tybost viread emtriva compleraeviplera emtricitabinerilpivirinetdf oral formulation dose day treatment hiv infection adult product market united states complera europe eviplera singletablet regimen treatment hiv fixeddose combination antiretroviral medication viread emtriva janssen rilpivirine atripla efavirenzemtricitabinetdf oral formulation dose day treatment hiv infection adult atripla singletablet regiman hiv intend standalone therapy combination antiretroviral fixeddose combination antiretroviral medication viread emtriva bristolmyers squibb companys bmss efavirenz truvada emtricitabinetdf oral formulation dose day combination therapy treat hiv infection adult fixeddose combination antiretroviral medication viread emtriva fda approve truvada combination safe sex practice reduce risk sexually acquire hiv infection adult high risk strategy call preexposure prophylaxis prep viread oral formulation nucleotide analog reverse transcriptase inhibitor dose day combination therapy treat hiv infection patient year age old european commission approve use viread combination antiretroviral agent treatment hivinfecte adolescent patient age year nucleoside reverse transcriptase inhibitor resistance toxicity precluding use firstline pediatric agent viread approve treatment hbv emtriva oral formulation nucleoside analog reverse transcriptase inhibitor dose day combination therapy treat hiv infection adult united states europe emtriva available oral solution approve combination therapy treat hiv infection child tybost pharmacokinetic enhancer dose day boost blood level certain hiv medicine tybost indicate boost agent hiv protease inhibitor atazanavir darunavir antiretroviral combination therapy adult hiv infection vitekta oral formulation integrase inhibitor dose day combination therapy treat hiv infection adult know mutation associate resistance elvitegravir active ingredient vitekta vitekta indicate use hiv treatment regimen include ritonavirbooste protease inhibitor liver disease vemlidy oral formulation oncedaily treatment taf adult hbv infection compensate liver disease vemlidy approve fda november european commission january epclusa oral formulation sofosbuvir velpatasvir pangenotypic singletablet regimen treatment adult genotype chronic infection epclusa singletablet regiman approve treatment patient hcv genotype need ribavirin epclusa week approve patient cirrhosis compensate cirrhosis childpugh combination ribavirin patient decompensate cirrhosis childpugh b c epclusa approve fda june european commission july harvoni oral formulation ledipasvir sofosbuvir dose day treatment genotype hcvhiv coinfection hcv genotype liver transplant recipient genotype infect patient decompensate cirrhosis europe harvoni indicate certain patient hcv genotype infection hcv genotype infection cirrhosis andor prior treatment failure hcvhiv co infection sovaldi oral formulation sofosbuvir dose day treatment hcv component combination antiviral treatment regimen sovaldi efficacy establish patient hcv genotype infection united states europe genotype infection europe include hepatocellular carcinoma meeting milan criterion await liver transplantation hcvhiv co infection viread oral formulation nucleotide analog reverse transcriptase inhibitor dose day treatment hbv adult compensate decompensate liver disease license glaxosmithkline inc gsk right commercialize viread treatment hbv china japan saudi arabia european commission approve use viread treatment hbv infection adolescent patient age year compensate liver disease evidence immune active disease viread approve treatment hiv infection hepsera adefovir dipivoxil oral formulation nucleotide analog polymerase inhibitor dose day treat hbv patient year age old license gsk right commercialize hepsera treatment hbv asia pacific latin america certain territory hematologyoncology zydelig idelalisib firstinclass pik delta inhibitor treatment certain blood cancer united states zydelig approve combination rituximab patient relapse cll rituximab consider appropriate therapy monotherapy patient relapse follicular bcell nonhodgkin lymphoma fl small lymphocytic lymphoma sll receive prior systemic therapy european union zydelig approve treatment cll fl cardiovascular letairis ambrisentan oral formulation endothelin receptor antagonist era indicate treatment pulmonary arterial hypertension pah group patients class ii iii symptom improve exercise capacity delay clinical worsen sublicense gsk right ambrisentan market gsk volibris ambrisentan pah territory outside united states ranexa ranolazine extendedrelease tablet treatment chronic angina licensed menarini international operation luxembourg sa rights ranexa territory outside united states lexiscan regadenoson injection indicate use pharmacologic stress agent radionuclide myocardial perfusion image mpi test detect characterize coronary artery disease patient unable undergo adequate exercise stress astella llc astella exclusive right manufacture sell regadenoson lexiscan united states rapidscan pharma solutions inc rps hold exclusive right manufacture sell regadenoson rapiscan europe certain territory outside united states receive royalty astella rps sale territory inflammationrespiratory cayston aztreonam inhalation solution inhale antibiotic treatment respiratory system cystic fibrosis patient seven year age old pseudomona aeruginosa p aeruginosa tamiflu oseltamivir phosphate oral antiviral available capsule form treatment prevention influenza b tamiflu approve treatment influenza child adult country include united states japan european union tamiflu approve prevention influenza child adults united states japan european union develop tamiflu f hoffmannla roche ltd hoffmannla roche inc roche roche exclusive right manufacture sell tamiflu worldwide subject obligation pay royalty base percentage net sale tamiflu ambisome amphotericin b liposome injection proprietary liposomal formulation amphotericin b antifungal agent treat invasive fungal infection cause fungal specie adult corporate partner astella pharma inc promote sell ambisome united states canada promote sell ambisome europe australia new zealand macugen pegaptanib sodium injection intravitreal injection antiangiogenic oligonucleotide treatment neovascular agerelate macular degeneration macugen develop eyetech inc eyetech technology license promote united states valeant pharmaceuticals inc valeant acquire eyetech valeant hold exclusive right manufacture sell macugen united states pfizer inc pfizer hold exclusive right manufacture sell macugen rest world receive royalty valeant pfizer base worldwide sale macugen antiviral product sale include sale hiv antiviral product hcv product billion billion billion respectively represent total revenue total revenue total revenue sale product billion billion billion respectively represent total revenue total revenue total revenue management discussion analysis financial condition result operation include item note segment information note consolidated financial statement include item annual report additional information relate sale product commercialization distribution international commercial sale operation marketing subsidiary country product market commercial team andor conjunction thirdparty distributor corporate partner commercial team promote product direct field contact physician hospital clinic healthcare provider generally grant thirdparty distributor exclusive right promote product territory specify period time agreement distributor provide collaborative effort distributor gilead obtain maintain regulatory approval product specify territory sell distribute epclusa harvoni sovaldi vemlidy descovy odefsey truvada atripla stribild complera viread genvoya emtriva tybost vitekta ranexa ambisome zydelig hepsera united states exclusively wholesale channel product sale large wholesaler mckesson corporation amerisourcebergen corporation cardinal health inc account total revenue year end december combine basis wholesaler account approximately product sale united states approximately total worldwide revenue letairis cayston distribute exclusively specialty pharmacy specialty pharmacy dispense medication complex chronic condition require high level patient education ongoing counseling sell distribute epclusa harvoni sovaldi vemlidy descovy odefsey truvada atripla stribild eviplera viread emtriva tybost vitekta genvoya ranexa ambisome zydelig hepsera europe country outside united states product approve commercial team thirdparty distributor corporate partner patient access priority increase access medicine people benefit regardless ability pay united states patient support assistance program help patient family understand access option assist patient understand insurance coverage financial assistance option eligibility free treatment therapy accessible uninsured individual need financial assistance support program unable afford copayment associate health insurance program half patient take hiv medicine united states receive federal state program substantially discount price long history work state aids drug assistance program adap provide low pricing hiv medicine price freeze institute adap extend end provide important support critical program evolve change healthcare environment develop world access gilead access program establish certain product hivaid viral hepatitis visceral leishmaniasis available substantially reduce price develop world today million people receive gilead hiv medicine low middleincome country enter number collaboration relate access product develop world include license generic manufacturer enter nonexclusive license agreement indian generic manufacturer grant right produce distribute generic version certain hiv hcv hbv product lowincome country world include india country gilead access program medicine patent pool mpp enter agreement mpp organization establish united nations increase global access highquality lowcost antiretroviral therapy sharing patent grant mpp nonexclusive license identify generic pharmaceutical manufacturer india specialize highquality production generic medicine grant sublicense indian manufacturer manufacture distribute generic version antiretroviral develop world sublicensee mpp free develop combination product pediatric formulation hiv medicine special partnership work national government local organization increase access hiv hcv medicine strengthen healthcare system example establish agreement national aids program myanmar donate generic version atripla people live hiv country provide hiv educational activity financial support strengthen countrys health system tanzania launch hiv testandtreat demonstration project holy see good samaritan foundation program goal enable screen patient hiv provide hiv therapy hivpositive individual year egypt agree provide sovaldi harvoni egyptian ministry health significantly reduce price addition partnership ministry health invest local hcv medical education prevention effort screen patient awareness initiative georgia establish agreement ministry labor health social affair georgia help eliminate hcv country project aim reduce number georgian infect hcv low rate new infection universal screen treatment prevention surveillance competition market product target number area include hiv liver disease cardiovascular hematologyoncology inflammationrespiratory disease commercially available product treatment disease face significant competition large global pharmaceutical biotechnology company specialize pharmaceutical firm generic drug manufacturer product compete available product base primarily efficacy safety tolerability acceptance doctor ease patient compliance ease use price insurance reimbursement coverage distribution marketing product mature private insurer government payer reduce reimburse patient increase pressure reduce price new brand generic product introduce major market ability maintain pricing market share affect hiv product hiv landscape competitive complex treatment trend continue evolve grow number hiv drug currently sell advanced stage clinical development competition current expect competitor erode revenue receive sale hiv product hiv product compete primarily product viiv healthcare viiv market fixeddose combination product compete descovy odefsey genvoya stribild compleraeviplera atripla truvada example product market viiv tivicay dolutegravir integrase inhibitor triumeq dolutegravirabacavirlamivudine singletablet antiretroviral regimen adversely impact sale hiv product addition viiv lamivudine compete emtricitabine active pharmaceutical ingredient emtriva component descovy odefsey genvoya stribild compleraeviplera atripla truvada tybost compete ritonavir market abbvie inc abbvie hiv product contain taf tdf andor emtrictabine belong nucleoside class antiviral therapeutic treatment paradigm hiv change market share likely decline face competition generic hiv product generic version lamivudine combivir lamivudine zidovudine available united states certain country generic version sustiva efavirenz component atripla available canada europe anticipate competition generic efavirenz united states december observe pricing pressure relate sustiva component atripla sale addition tdf active pharmaceutical ingredient stribild compleraeviplera atripla truvada main active pharmaceutical ingredient viread expect face generic competition united states european union country emtricitabine active pharmaceutical ingredient truvada face generic competition european union truvada expect face generic competition european union country outside united states liver disease product continue face increase competition hcv market hcv product epclusa harvoni sovaldi compete viekira pak ombitasvir paritaprevir ritonavir tablet copackage dasabuvir tablet viekira xr dasabuvir ombitasvir paritaprevir ritonavir market abbvie zepatier elbasvir grazoprevir market merck co inc merck daklinza daclastavir market bms olysio simeprevir market janssen therapeutic expect new hcv product launch competitor competition current expect competitor negatively impact ability maintain pricing hcv market share expect pricing pressure hcv market continue hbv product vemlidy viread hepsera face competition exist expect therapy treat patient hbv hbv product face competition baraclude entecavir oral nucleoside analog market bm generic entecavir hbv product compete tyzekasebivo telbivudine oral nucleoside analog market novartis pharmaceutical corporation novartis cardiovascular product letairis competes tracleer bosentan opsumit macitentan market actelion pharmaceutical inc adcirca tadalafil market united therapeutics corporation pfizer ranexa compete predominantly generic compound distinct class drug treatment chronic angina united states include generic andor brand betablocker calcium channel blocker longacte nitrate addition surgical treatment intervention coronary artery bypass graft percutaneous coronary intervention option angina patient perceive healthcare practitioner prefer method treat cardiovascular disease underlie cause angina numerous market generic andor brand pharmacologic stress agent compete lexiscan hematologyoncology product zydelig competes imbruvica ibrutinib market pharmacyclics inc gazyva obinutuzumab market genentech member roche group treanda bendamustine hydrochloride market cephalon inc inflammationrespiratory product cayston compete primarily tobi tobramycin inhalation solution inhale medication market novartis treatment cystic fibrosis patient lung contain p aeruginosa bacterial infection tamiflu compete relenza zanamivir influenza neuraminidase inhibitor market gsk product sell generic competitor product ambisome compete vfend voriconazole market pfizer caspofungin product develop merck market cancidas united states caspofungin ambisome compete lipidbase amphotericin b product include abelcet amphotericin b lipid complex injection sell enzon pharmaceuticals inc united states canada japan zeneus pharma ltd europe amphotec amphotericin b cholesteryl sulfate complex injection sell river pharmaceutical llc worldwide anfogen amphotericin b liposomal sell genpharma sa argentina bms numerous generic manufacturer sell conventional amphotericin b compete ambisome addition aware lipid formulation claim similarity ambisome available outside united states formulation reduce market demand ambisome furthermore manufacture lipid formulation amphotericin b complex formulation find unsafe sale ambisome negatively impact association addition number company pursue development technology competitive exist product research program compete company include specialized pharmaceutical firm large pharmaceutical company act independently pharmaceutical company furthermore academic institution government agency public private organization conduct research seek patent protection establish collaborative arrangement competitive product program competitor gain market share product adversely affect result operation stock price collaborative relationship business strategy establish collaboration company university medical research institution assist clinical development andor commercialization certain product product candidate provide support research program evaluate opportunity acquire product right product technology complementary business company university medical research institution information certain relationship include ongoing financial accounting impact business note collaborative arrangement note consolidated financial statement include item annual report commercial collaboration currently number collaboration corporate partner manufacture sale distribution andor marketing product territory worldwide follow commercial collaboration significant financial statement perspective significant ongoing collaboration activity exist bms north america enter collaboration arrangement bms develop commercialize singletablet regiman contain truvada bmss sustiva efavirenz united states combination approve use united states sell brand atripla bms structure collaboration joint venture operate limited liability company name bristolmyers squibb gilead sciences llc consolidate bms grant royaltyfree sublicense joint venture use respective company own technology return grant license joint venture use intellectual property result collaboration bms amend joint venture collaboration agreement allow joint venture sell atripla canada economic interest joint venture hold bms include share revenue outofpocket expense base portion net selling price atripla attributable efavirenz truvada net selling price truvada change time relative net selling price efavirenz bmss respective economic interest joint venture vary annually bms share marketing sale effort start second quarter limited number activity jointly manage party long coordinate detail promotional activity united states party reduce joint promotional effort launch complera august stribild august party continue collaborate activity manufacture regulatory compliance pharmacovigilance daily operation joint venture govern joint committee form bms gilead responsible accounting financial reporting tax reporting manufacturing product distribution joint venture party provide respective bulk active pharmaceutical ingredient joint venture approximate market value agreement continue terminate mutual agreement party addition party terminate party participation collaboration day launch generic version party single agent product double agent product terminate party right continue sell atripla continue party obligate pay terminate party certain royalty threeyear period follow effective date termination loss exclusivity united states sustiva expect december december joint venture hold efavirenz active pharmaceutical ingredient purchase bms bmss estimate net selling price efavirenz market amount primarily include inventory consolidate balance sheet december europe gilead sciences ireland uc whollyowne subsidiary bms enter collaboration agreement bms commercialize distribute atripla european union iceland liechtenstein norway switzerland collectively european territory party form limited liability company consolidate manufacture atripla distribution european territory efavirenz purchase bms bmss estimate net selling price efavirenz european territory responsible manufacturing product distribution inventory management warehouse local subsidiary primary responsibility order fulfillment collection receivables customer relation handle sale return territory bms promote atripla general party share revenue outofpocket expense proportion net selling price component atripla truvada efavirenz start limited number activity jointly manage party long coordinate detail promotional activity european territory responsible accounting financial reporting tax reporting collaboration december december efavirenz purchase bms bmss estimate net selling price efavirenz european territory primarily include inventory consolidate balance sheet party form limited liability company hold marketing authorization atripla european territory primary responsibility regulatory activity major market country party agree independently continue use commercially reasonable effort promote atripla agreement terminate expiration lasttoexpire patent afford market exclusivity atripla component european territory addition december party terminate agreement reason termination effective calendar quarter notice termination nonterminate party right continue sell atripla continue party obligate pay terminate party certain royalty threeyear period follow effective date termination event continue party decide sell atripla effective date termination date atripla withdraw country date party assume distribution atripla whichever early janssen enter collaboration agreement janssen develop commercialize fixeddose combination truvada janssens rilpivirine agreement amend combination approve united states european union sell brand complera united states eviplera european union amendment expand collaboration include singletablet regiman contain janssen rilpivirine emtricitabine tenofovir alafenamide odefsey agreement janssen grant exclusive license compleraeviplera odefsey worldwide right distribute combination product country include mexico russia japan party restrict combine drug drug product similar component compleraeviplera odefsey responsible manufacturing compleraeviplera odefsey lead role registration distribution commercialization product country janssen distribute janssen exercise right codetail combination product country gilead sell party selling party set price product party share revenue base ratio net selling price party component subject certain restriction adjustment retain specify percentage janssen share revenue major market party terminate collaboration agreement respect product country product withdraw market country respect product country party materially breach agreement respect product agreement party obligation share revenue expire productbyproduct countrybycountry basis janssen patent provide exclusivity product expire later tenth anniversary commercial launch product terminate agreement cause respect country sell product case janssen right sell party country product launch market few year japan tobacco japan tobacco inc japan tobacco grant exclusive right develop commercialize elvitegravir novel hiv integrase inhibitor country world exclude japan japan tobacco retain right agreement responsible seek regulatory approval territory require use diligent effort commercialize elvitegravir treatment hiv infection bear cost expense associate commercialization effort receive approval stribild elvitegravircontaine product fda august european commission receive approval genvoya elvitegravircontaine product fda european commission november agreement obligation pay royalty japan tobacco terminate productbyproduct basis patent provide exclusivity product expire later tenth anniversary commercial launch product terminate agreement reason case license grant japan tobacco terminate party terminate agreement response material breach party research collaboration number collaboration partner research development rd certain compound drug candidate research collaboration significant financial statement perspective research development rd philosophy strategy develop bestinclass drug improve safety efficacy unmet medical need intend continue commit significant resource internal rd opportunity external business development activity product development effort cover wide range medical condition include hivaid liver disease hcv hbv hematologyoncology cardiovascular inflammationrespiratory disease research scientist foster city fremont san dimas oceanside california seattle washington alberta canada engage discovery development new molecule technology hope lead approval new medicine address unmet need development product candidate subject risk uncertaintie risk uncertainty include ability enroll patient clinical trial possibility unfavorable result clinical trial need modify delay clinical trial perform additional trial risk fail obtain regulatory approval result product candidate successfully commercialize drug development inherently risky product candidate fail drug development process summary key product candidate correspond current stage development product candidate treatment hiv product candidate description product phase bictegravirftaf singletablet regimen bictegravir nonbooste integrase inhibitor ftaf evaluate treatment hiv infection descovy descovy evaluate prep product phase gs gs tlr agonist evaluate treatment hiv infection product candidate treatment liver disease product candidate description market application pende singletablet regimen sofosbuvir velpatasvir singletablet regimen sofosbuvir velpatasvir voxilaprevir pangenotypic ns protease inhibitor voxilaprevir evaluate treatment hcv product phase selonsertib selonsertib ask inhibitor evaluate treatment nash product phase gs gs tlr agonist evaluate treatment hbv selonsertib selonsertib ask inhibitor evaluate treatment alcoholic hepatitis gs gs fxr agonist evaluate treatment nash primary biliary cirrhosis primary sclerosing cholangitis gs gs acc inhibitor evaluate treatment nash product candidate treatment hematologyoncology product candidate description product phase idelalisib idelalisib pik delta inhibitor evaluate treatment relapse refractory cll gs gs mmp mab inhibitor evaluate treatment gastric cancer product phase entospletinib entospletinib syk inhibitor evaluate treatment hematological malignancy acute myeloid leukemia gs gs btk inhibitor evaluate treatment bcell malignancy product phase gs gs mmp mab inhibitor evaluate treatment solid tumor gs gs bet inhibitor evaluate treatment solid tumor product candidate treatment inflammationrespiratory disease product candidate description product phase filgotinib jak inhibitor evaluate treatment rheumatoid arthritis crohns disease filgotinib ulcerative colitis product phase filgotinib jak inhibitor evaluate treatment inflammatory disease filgotinib entospletinib entospletinib syk inhibitor evaluate treatment chronic graft versus host disease presatovir presatovir fusion inhibitor evaluate treatment respiratory syncytial virus gs gs mmp mab inhibitor evaluate treatment cystic fibrosis rheumatoid arthritis gs gs syk inhibitor evaluate treatment rheumatoid arthritis product candidate product candidate description product phase gs gs nuc inhibitor evaluate treatment ebola virus infection total rd expense billion billion billion rd expense increase compare primarily overall progression clinical study include ongoing milestone payment purchase fda priority review voucher upfront collaboration expense relate license collaboration agreement galapago purchase nimbus apollo inc nimbus record process rd impairment charge relate momelotinib simtuzumab addition internal discovery clinical development program seek add portfolio product product acquisition license collaboration january close license collaboration agreement galapago clinicalstage biotechnology company base belgium development commercialization filgotinib jakselective inhibitor investigate inflammatory disease indication filgotinib phase clinical trial potential treatment rheumatoid arthritis crohns disease ulcerative colitis acquire nimbus privately hold company acc inhibitor program evaluate potential treatment nash hepatocellular carcinoma disease patent proprietary right european patent expiration number foreign patent patent application right patent relate compound product technology certain issue patent enforceable provide adequate protection pende patent application result issue patent follow table show estimate expiration date include patent term extension supplementary protection certificate andor pediatric exclusivity grant united states europe primary typically compound patent phase product candidate patent cover ranolazine compound active ingredient ranexa instead discover sustainedrelease formulation ranolazine achieve therapeutic plasma level patent obtain formulation characteristic plasma level achieve product candidate singletablet regimen estimate patent expiration date provide correspond late expiring compound patent active ingredient singletablet regimen phase product candidate patent expiration product candidate treatment hiv eu singletablet regimen bictegravir ftaf product candidate treatment liver disease singletablet regimen sofosbuvir velpatasvir voxilaprevir treatment hcv selonsertib treatment nash product candidate treatment hematologyoncology idelalisib treatment relapse refractory cll gs treatment gastric cancer product candidate treatment inflammation disease filgotinib treatment rheumatoid arthritis filgotinib treatment crohns disease filgotinib treatment ulcerative colitis date parenthesis reflect estimate expiration date patent issue currently pende application estimate expiration date include potential additional exclusivity eg patent term extension supplementary protection certificate pediatric exclusivity grant follow table show actual estimate expiration date include patent term extension supplementary protection certificate andor pediatric exclusivity grant united states europe primary typically compound patent market product product fix dose combination singletablet regimen eg truvada atripla compleraeviplera stribild genvoya odefsey descovy estimate patent expiration date provide correspond late expiring compound patent active ingredient singletablet regimen product patent expiration eu hepsera ambisome macugen tamiflu letairis viread ranexa atripla cayston emtriva truvada lexiscan compleraeviplera vitekta zydelig sovaldi stribild genvoya tybost harvoni descovy odefsey epclusa vemlidy date parenthesis reflect estimate expiration date patent issue currently pende application estimate expiration date include potential additional exclusivity eg patent term extension supplementary protection certificate pediatric exclusivity grant gilead watson laboratories inc watson reach agreement settlement patent litigation relate letairis gilead teva pharmaceutical teva reach agreement principle settle ongoing patent litigation concern patent protect tenofovir disoproxil fumarate viread truvada atripla product agreement teva allow launch generic version viread december gilead lupin limited lupin reach agreement settle patent litigation prior issuance court decision agreement lupin allow launch generic version ranexa february patent protection certain challenge patent proprietary right important business properly draft enforceable patent difficult competitor use technology create competitive product difficult competitor obtain patent prevent technology create business strategy actively seek patent protection united states internationally file additional patent application appropriate cover improvement compound product technology patent cover certain active pharmaceutical ingredient api truvada atripla stribild compleraeviplera genvoya odefsey descovy vitekta emtriva letairis hepsera hold party acquire exclusive right patent agreement party patent cover ranolazine compound active ingredient ranexa instead discover sustainedrelease formulation ranolazine achieve therapeutic plasma level patent obtain formulation characteristic plasma level achieve patent cover active ingredient ambisome obtain patent certain product year marketing approval obtain product patent limited life begin run prior commercial sale relate product commercial value patent limit able apply patent term extension supplementary protection certificate country example extension patent supplementary protection certificate product grant united states number european country compensate delay obtain marketing approval similar patent term extension available product develop certain obtain country important infringe valid patent party infringe valid patent party prevent commercialize product require obtain license party able obtain alternative technology require license reasonable term fail obtain license alternative technology unable develop commercialize product example aware body patent relate operation letairis education access program leap restrict distribution program design support letairis aware patent patent application own party claim cover use sofosbuvir use combination sofosbuvir ledipasvir patent application confidential period time patent issue know competitor file patent application technology cover pende application invent file application direct technology subject patent application competitor file patent application receive patent obtain additional patent proprietary right block compete product addition competitor file patent application cover technology participate interferencederivation proceeding litigation determine right patent litigation interferencederivation proceeding unpredictable expensive ultimately successful result operation adversely affect event patent relate pharmaceutical biopharmaceutical biotechnology product compound process cover exist compound product process likely file future provide complete adequate protection future litigation proceeding enforcement validity exist patent future patent result invalidation patent substantially reduce protection time time certain individual entity challenge patent pende patent application patent application file collaborative partner result issuance patent result patent provide adequate protection result able prevent party develop compound product closely relate developed develop addition certain country south america africa asia include brazil china provide effective enforcement patent thirdparty manufacturer able sell generic version product country litigation relate sofosbuvir january acquire pharmasset inc pharmasset acquisition acquire sofosbuvir nucleotide analog act inhibit replication hcv december receive fda approval sofosbuvir know commercially sovaldi october receive approval fixeddose combination ledipasvir sofosbuvir know commercially harvoni june receive approval fixeddose combination sofosbuvir velpatasvir know commercially epclusa receive number contractual intellectual property claim sofosbuvir carefully consider claim prior follow acquisition believe merit predict ultimate outcome claim range loss patent patent application claim sofosbuvir sovaldi chemical entity metabolite fixeddose combination ledipasvir sofosbuvir harvoni sofosbuvir velpatasvir epclusa party obtain right patent allegedly prevent attempt prevent commercialize epclusa harvoni sovaldi example aware patent patent application own party future allege party cover use epclusa harvoni sovaldi predict ultimate outcome intellectual property claim relate epclusa harvoni sovaldi spend continue spend significant resource defend claim party successfully obtain valid enforceable patent successfully prove infringement patent epclusa harvoni andor sovaldi prevent sell product able obtain license patent license available commercially reasonable term interference proceeding litigation idenix pharmaceuticals inc idenix universita degli studi di cagliari udsg centre national de la recherche scientifique luniversite montpellier ii february receive notice patent trademark office uspto declare interference idenix interference patent patent idenixs pende patent application determine invent certain nucleoside compound january uspto patent trial appeal board ptab determine pharmasset idenix invent compound idenix appeal ptab decision district court district delaware stayed appeal pende outcome appeal interference involve idenixs patent patent describe december receive request uspto declare interference second idenix interference pende patent application idenixs patent patent include claim direct method treat hcv nucleoside compound march ptab determine pharmasset idenix invent claim method treat hcv idenix appeal decision district court district delaware court appeal federal circuit cafc cafc hear oral argument september awaiting decision file motion dismiss appeal delaware court stay appeal relate second idenix interference believe idenix claim involve second idenix interference similar foreign patent claim compound metabolite use thereof invalid result file impeachment action federal court canada invalidate idenix canadian patent patent canadian patent correspond patent idenix assert commercialization sovaldi canada infringe patent canadian patent correspond patent invalid november canadian court hold idenixs patent invalid patent valid idenix appeal decision canadian federal court appeal november appeal hearing hold january await decision file similar legal action norway oslo district court seek invalidate idenixs norwegian patent correspond patent september idenix file invalidation action norwegian proceeding norwegian patent correspond patent march norwegian court find claim idenix norwegian patent invalid upheld validity claim patent idenix appeal decision norwegian court appeal april court appeal issue decision invalidate idenix patent uphold patent idenix file appeal january file legal action federal court australia seek invalidate idenixs australian patent correspond patent april idenix assert commercialization sovaldi australia infringe australian patent correspond patent march australian court revoke idenixs australian patent idenix appeal decision appeal hearing hold november await decision march european patent office epo grant idenix european patent patent correspond patent day patent grant file opposition epo seek revoke patent opposition hearing hold february epo rule favor revoke patent idenix appeal march idenix initiate infringement proceeding united kingdom uk germany france allege commercialization sovaldi infringe uk german french counterpart patent trial hold uk october december high court justice england wale uk court invalidate challenge claim patent multiple ground idenix appeal november appeal court affirm uk court decision invalidate idenixs patent march german court dsseldorf determine idenix patent highly likely invalid stay infringement proceeding pende outcome opposition hearing hold epo february idenix appeal decision german court staying proceeding idenixs request french proceeding stay idenix award patent correspond patent japan china december idenix universita degli studi di cagliari udsg centre national de la recherche scientifique luniversit montpellier ii sue district court district delaware allege commercialization sofosbuvir infringe patent interference exist patent patent december idenix udsg sue district court district massachusetts allege commercialization sofosbuvir infringe patent nos patent patent june court transfer massachusetts litigation district court district delaware idenix acquire merck co inc merck august prior trial december idenix commit covenant sue respect claim arise patent relate sofosbuvir withdraw patent trial addition idenix decline litigate patent infringement action trial light appeal currently pende cafc january district court stay idenixs infringement claim patent pende outcome appeal interference decision patent describe jury trial hold december remain patent december jury find willfully infringe assert claim patent award idenix billion past damage party file posttrial motion briefing quarter expect judge rule fourth quarter judge issue ruling case cafc predict certainty ultimate outcome litigation believe jury verdict error error court respect certain ruling trial confident merit case vigorously pursue position posttrial motion appeal expect argument forthcome posttrial motion appeal focus argument judge jury properly construe gilead infringe claim patent ii patent invalid failure properly describe claim invention iii patent invalid enable skill art practice claim invention information note commitment contingency legal proceeding note consolidated financial statement include item annual report jurys verdict upheld appeal require pay material time magnitude payment material adverse impact result operation litigation merck august merck contact request pay royalty sale sofosbuvir obtain license patent patent patent patent coown ionis pharmaceuticals inc patent cover compound include relate sofosbuvir file lawsuit august district court northern district california seek declaratory judgment merck patent invalid infringe patent prosecution merck amend patent application attempt cover compound relate sofosbuvir initially march jury determine establish merck patent invalid lack write description lack enablement award merck million damage june court rule gilead favor defense unclean hand determine merck recover damage patent judge determined merck require pay attorney fee exceptional nature case fee owe merck determine court merck file notice appeal court appeal federal circuit court decision defense unclean hand appeal issue relate invalidity merck patent decision defense unclean hand reverse appeal merck patent uphold require pay damage royalty sale sofosbuvircontaine product follow appeal event judge indicate determine royalty necessary conclusion appeal case litigation university minnesota university minnesota university obtain patent patent purport broadly cover nucleosides antiviral anticancer activity august university file lawsuit district court district minnesota allege commercialization sofosbuvircontaine product infringe patent believe patent invalid infringe continue commercialization sofosbuvir european patent claim february party file opposition epo request revocation grant european patent cover sofosbuvir expire october epo uphold validity certain claim sofosbuvir patent anticipate challenger appeal decision favor patent appeal process year january party file opposition epo request revocation grant european patent cover taf expire march party file opposition epo request revocation grant european patent cover cobicistat expire confident strength patent predict ultimate outcome opposition unsuccessful defend opposition patent claim narrowed revoke patent protection sofosbuvir taf cobicistat europe substantially shorten eliminate entirely patent revoke european patent grant covering compound exclusivity base entirely regulatory exclusivity grant european medicine agency ema sovaldi grant regulatory exclusivity prevent generic sofosbuvir enter european union year follow approval sovaldi january lose exclusivity sovaldi prior expect revenue result operation negatively impact year include succeed year exclusivity lose cause stock price decline litigation generic manufacturer approval process product fda grant new chemical entity nce exclusivity period manufacturer application approval generic version product approve generic manufacturer challenge patent protect product grant nce exclusivity year prior end nce exclusivity period generic manufacturer seek continue seek fda approval similar identical drug abbreviate new drug application anda application form typically manufacturer seek approval generic drug sale generic version product early patent expiration significant negative effect revenue result operation seek approval generic version product nce status generic company submit anda fda year brand product approval sofosbuvir date fall december consequently possible generic file anda sovaldi december current legal proceeding significance generic manufacturer include hiv product november december august receive notice teva submit abbreviate new drug submission and canadian minister health request permission manufacture market generic version truvada atripla viread notice teva allege patent associate truvada atripla viread invalid unenforceable andor infringe tevas manufacture use sale generic version product file lawsuit teva federal court canada seek order prohibition approval application december court issue order prohibit canadian minister health approving tevas generic version viread truvada atripla product expiry patent july teva appeal decision court decision rule validity patent accordingly issue appeal canadian minister health prohibit approve tevas product november teva enter settlement agreement resolve ongoing contested proceeding concern tevas ands generic version truvada atripla viread gilead patent associate truvada atripla viread june receive notice apotex inc apotex submit and canadian minister health request permission manufacture market generic version truvada separate and request permission manufacture market generic version viread notice apotex allege patent associate truvada patent associate viread invalid unenforceable andor infringe apotexs manufacture use sale generic version truvada viread august file lawsuit apotex federal court canada seek order prohibition approval and hear case hold april july court issue order prohibit canadian minister health approving apotexs generic version viread product expiry patent july court decline prohibit approval apotexs generic version truvada product court decision rule validity patent launch apotexs generic version truvada product risk infringement patent include patent unable assert present lawsuit liability damage apotex appeal court decision february receive notice mylan pharmaceuticals inc mylan submit anda fda request permission manufacture market generic version tybost cobicistat notice mylan allege patent cover cobicistat invalid obvious mylan generic product infringe invalid claim march file lawsuit mylan district court district delaware district court northern district west virginia january receive letter mylan notify submit duplicate anda fda product currently evaluate mylan letter trial delaware schedule january patent suit cover tybost list orange book stribild genvoya letairis february receive notice watson laboratories inc watson submit anda fda request permission manufacture market generic version letairis notice watson allege patent associate ambrisentan tablet invalid unenforceable andor infringe watson manufacture use sale generic version letairis april file lawsuit watson district court district new jersey infringement patent january reach agreement watson settle litigation june receive notice sigmapharm laboratory llc sigmapharm submit anda fda request permission manufacture market generic version letairis notice sigmapharm allege patent associate ambrisentan tablet invalid unenforceable andor infringe sigmapharm manufacture use sale generic version letairis june file lawsuit sigmapharm district court district new jersey infringement patent date trial sigmapharm set estimate occur second quarter predict ultimate outcome action spend significant resource enforce defend patent unsuccessful lawsuit claim patent narrow invalidated patent protection product substantially shorten patent cover product invalidate fda canadian minister health approve request manufacture generic version products united states canada respectively prior expiration date patent sale generic version product early patent expiration significant negative effect revenue result operation taf litigation january aids healthcare foundation inc ahf file complaint district court northern district california gilead japan tobacco inc japan tobacco international usa jt emory university emory april ahf amend complaint add janssen johnson johnson inc jj defendants ahf claim patent nos invalid addition ahf claim gilead independently jt akros janssen jj violate federal state antitrust unfair competition law market sale taf offer taf fixeddose combination product elvitegravir cobicistat emtricitabine genvoya fixeddose combination product elvitegravir rilpivirine odefsey fixeddose combination product elvitegravir descovy ahf seek declaratory judgment invalidity patent monetary damage jt janssen jj file motion dismiss ahfs claim ahf oppose june hearing hold motion dismiss july judge grant defendant motion dismiss ahfs claim ahf appeal court decision dismiss challenge validity taf patents department justice investigation june receive subpoena attorney office northern district california request document relate manufacture relate quality distribution practice complera atripla truvada viread emtriva hepsera letairis cooperate government inquiry april united states department justice inform follow investigation decline intervene false claim act lawsuit file employee april employee serve amend complaint january federal district court issue order grant entirety prejudice motion dismiss amend complaint february plaintiff file second amend complaint june federal district court issue order grant motion dismiss second amend complaint july plaintiff file notice appeal court appeal ninth circuit february receive subpoena attorney office district massachusetts request document relate support c organization provide financial assistance patient hcv product document concern provision financial assistance patient company disclose similar inquiry cooperate inquiry matter party legal action arise ordinary course business believe legal action material adverse impact consolidate business financial position result operation trade secret rely unpatented trade secret improvement unpatente internal knowhow technological innovation example great deal liposomal manufacturing expertise key component liposomal technology cover patent instead protect trade secret protect right mainly confidentiality agreement corporate partner employee consultant vendor agreement provide confidential information develop known individual course relationship keep confidential disclose party specify circumstance case employee agreement provide invention individual employ exclusive property certain party comply confidentiality agreement adequate remedy breach trade secret know independently discover competitor rd agreement invention jointly own corporate partner case exclusive property party certain circumstance difficult determine own particular invention dispute arise invention trade secret confidential information know independent discover competitor enter dispute ownership invention business result operation adversely affect manufacture raw material manufacturing strategy contract party manufacture majority api solid dose product rely corporate partner manufacture certain product additionally lease manufacturing facility foster city san dimas oceanside california edmonton alberta canada cork ireland manufacture certain product api clinical andor commercial use manufacturing product contract party manufacture certain api clinical commercial purpose include epclusa harvoni sovaldi truvada atripla stribild compleraeviplera viread genvoya odefsey descovy vemlidy emtriva tybost vitekta ranexa ambisome zydelig cayston generally use multiple thirdparty contract manufacturer manufacture api product exclusive manufacturer ambrisentan api letairis supplier qualify api letairis rely thirdparty contract manufacturer manufacture oral liquid tablet capsule product example use multiple thirdparty contract manufacturer tablet epclusa harvoni sovaldi truvada atripla stribild compleraeviplera viread genvoya odefsey descovy vemlidy tybost vitekta letairis ranexa zydelig hepsera emtriva encapsulation complete thirdparty contract manufacturer liquid filling emtriva oral solution addition rely thirdparty contract manufacturer manufacture aseptic product ambisome cayston manufacture agreement corporate partner roche party responsible manufacturing tamiflu agreement roche joint manufacturing committee compose representative roche gilead opportunity review roche exist manufacturing capacity tamiflu global plan manufacture tamiflu astella llc corporate partner lexiscan united states responsible commercial manufacture supply product united states dependent single supplier api lexiscan future product continue develop additional manufacturing capability establish additional thirdparty supplier manufacture sufficient quantity product candidate undertake clinical trial manufacture sufficient quantity product approve commercial sale manufacturing facility foster city california facility conduct process chemistry research development activity manufacture api clinical trial oversee thirdparty contract manufacturer san dimas california facility package label solid oral dosage form product include epclusa harvoni sovaldi truvada atripla stribild compleraeviplera viread genvoya odefsey descovy vemlidy emtriva ranexa zydelig label hepsera letairis manufacture label ambisome cayston san dimas facility depend single supplier high quality cholesterol api manufacture ambisome exclusive supplier key drug product intermediate ambisome event disaster include earthquake equipment failure difficulty unable replace manufacturing capacity timely manner unable manufacture ambisome meet market need utilize cork ireland facility primarily solid dose tablet manufacturing certain antiviral product product packaging activity package label drug product epclusa harvoni sovaldi truvada atripla stribild compleraeviplera viread genvoya odefsey descovy vemlidy tybost vitekta label hepsera emtriva facilities cork ireland perform quality control testing final labeling secondary packaging ambisome cayston final release product european union facility distribute product european union international market dublin ireland site edmonton alberta facility canada carry process research scaleup clinical development candidate manufacture api investigational commercial product conduct chemical development activity improve exist commercial manufacturing process manufacture api letairis hepsera edmonton site oceanside california facility design equip produce biologic compound toxicological phase phase clinical study use facility process development manufacture gs bulk drug substance investigational mmp mab inhibitor biologic thirdparty manufacturer thirdparty manufacturer corporate partner independent entity subject unique operational financial risk control thirdparty manufacturer corporate partner fail perform require impair ability deliver product timely basis receive royalty cause delay clinical trial application regulatory approval writeoff cost manufacturing batch fail pass quality inspection meet regulatory approval extent risk materialize affect performance obligation financial result adversely affect addition thirdparty manufacturer corporate partner able produce product limit number facility limited manufacturing capacity certain product believe technology use manufacture product proprietary product manufacture thirdparty contract manufacturer disclose necessary aspect technology enable manufacture product agreement thirdparty manufacturer intend restrict manufacturer reveal technology certain thirdparty manufacturer comply restriction addition thirdparty manufacturer develop technology relate work perform need manufacture product required enter additional agreement thirdparty manufacturer want use technology allow manufacturer use technology thirdparty manufacturer refuse allow use technology demand term use technology acceptable regulation manufacturing process manufacturing process pharmaceutical product highly regulate regulator shut manufacturing facility believe comply regulation thirdparty manufacturer corporate partner subject current good manufacturing practice extensive regulation govern manufacturing process stability testing record keep quality standard define fda ema similar regulation effect country manufacture operation subject routine inspection regulatory agency example receive letter fda relate extent method revalidation conduct stability program oversight audit trail reviewdata management quality management system gap complete file response observation fda unable remedy deficiency cite fda extent additional deficiency cite fda future inspection currently market product time regulatory approval product development adversely affect risk regulatory agency country marketing application pende undertake similar additional review apply heighten standard review delay regulatory approval product country approval product candidate delay production market product interrupt anticipate revenue stock price adversely affect access supply material need access certain supply product conduct clinical trial manufacture product unable purchase sufficient quantity material find suitable alternate material timely manner development effort product candidate delay ability manufacture product limit limit ability generate revenue example significant portion raw material intermediate manufacture antiviral product supply thirdparty manufacturer corporate partner outside united states result political economic factor specific country region include change interpretation trade regulation compliance requirement tax legislation limit prevent party outside united states supply material adversely affect ability manufacture supply antiviral product meet market need material adverse effect operating result seasonal operation backlog worldwide product sale reflect significant degree seasonality operate market characterize short lead time absence significant backlog believe backlog information material business government regulation operation activity subject extensive regulation numerous government authority united states countries united states european union country drug subject rigorous regulation federal state statute regulation govern testing manufacture safety efficacy labeling storage record keeping approval advertising promotion product result regulation product development product approval process expensive time consume regulatory requirement applicable drug development approval subject change example december president obama sign law st century cure act contain broad range measure aim spur drug discovery development delivery legal regulatory change impact operation future country regulatory agency fda united states ema european union approve drug sell respective country country general process drug approval united states summarize country include country european union japan similar regulatory structure preclinical testing test drug candidate human study drug laboratory experiment animal generate datum support drug candidate potential benefit safety submit datum fda investigational new drug ind application seek approval test compound human clinical trial fda accept ind drug candidate study human clinical trial determine drug candidate safe effective clinical trial involve separate phase overlap year expensive phase subject considerable regulation follow phase drug candidate give small number healthy human control subject patient suffer indicate disease test safety dose tolerance pharmacokinetic metabolism distribution excretion phase drug candidate give limited patient population determine effect drug candidate treat disease good dose drug candidate possible effect safety risk drug candidate uncommon drug candidate appear promise phase clinical trial fail rigorous phase clinical trial phase drug candidate appear effective safe phase clinical trial phase clinical trial commence confirm result phase clinical trial conduct long term involve significantly large population conduct numerous site different geographic region carefully design provide reliable conclusive datum safety benefit drug candidate uncommon drug candidate appear promise phase clinical trial fail rigorous extensive phase clinical trial fda approval process believe datum clinical trial acceptable benefitrisk profile submit appropriate filing usually form nda supplemental nda fda seek approval sell drug candidate particular use fda hold public hear independent advisory committee expert advisor ask additional question make recommendation drug candidate committee make recommendation fda binding generally follow fda fda agree compound meet require level safety efficacy particular use allow sell drug candidate united states use unusual fda reject application believe drug candidate safe efficacious believe datum submit reliable conclusive point process development drug candidate stop number reason include safety concern lack treatment benefit certain clinical trial currently conduct conduct future complete successfully specified time period choose fda require delay suspend clinical trial time appear patient expose unacceptable health risk drug candidate appear sufficient treatment benefit fda require phase nonregistrational study explore scientific question characterize safety efficacy commercial use drug fda require provide additional data information improve manufacturing process procedure facility require extensive surveillance monitor safety benefit product candidate determine file contain adequate evidence safety benefit drug addition fda approve drug limit use drug fda withdraw approval believe comply regulatory standard problem uncover occur approval addition obtain fda approval drug obtain fda approval manufacturing facility drug sell include company manufacture drug facility subject periodic inspection fda fda approve foreign establishment manufacture product sell united states facility subject periodic regulatory inspection manufacturing facility locate california include oceanside san dimas facility license state california compliance local regulatory requirement manufacture facility locate canada include edmonton alberta facility facility locate near dublin cork ireland obtain local license permit compliance local regulatory requirement drug treat life threaten disease condition adequately address exist drug development program design address unmet medical need designate fast track candidate fda eligible priority review drug treatment hiv infection designate use president emergency plan aid relief qualify expedite priority review rest world drug subject extensive regulation outside united states european union centralize approval procedure authorize marketing product country european union include major country europe centralize approval procedure approval country european union obtain approval country european union simplified application process mutual recognition procedure decentralize procedure rely principle mutual recognition receive regulatory approval european registration procedure separate pricing reimbursement approval require country european union requirement approval manufacturing facility product approve sale european regulatory authority price reimbursement successful commercialization product depend availability governmental thirdparty payer reimbursement cost product relate treatment market sell product government health authority private health insurer organization generally provide reimbursement united states european union japan significant potentially significant market product product candidate government authority thirdparty payer increasingly attempt limit regulate price medical product service significant portion sale majority product subject substantial discount list price addition nonretail sector united states include government institution include state adap veterans administration va correctional facility large health maintenance organization tend consistent term buy pattern cause quarteroverquarter fluctuation necessarily mirror patient demand product federal state budget pressure include sequestration annual grant cycle federal state fund cause purchasing pattern reflect patient demand product example quarter certain prior year observe large nonretail purchase hiv product number state adap exceed patient demand believe purchase drive grant cycle federal adap fund additionally second half experience fluctuation va new hcv patient start purchase pattern va funding expect continue experience fluctuation purchase pattern nonretail customer result fluctuation product sale revenue earning future light global economic downturn budget crisis face european country observe variation purchase pattern induce cost containment measure europe believe measure cause government agency purchaser reduce inventory product distribution channel decrease revenue cause fluctuation product sale earning continue trend future addition future sale hcv product difficult estimate demand depend extent reimbursement hcv product private government payer light continued fiscal debt crisis experience country european union japan government announce implement measure manage healthcare expenditure continue experience global pricing pressure result large discount rebate product delay reimbursement negatively impact product sale result operation private public payer choose exclude hcv product formulary coverage list limit type patient coverage provide negatively impact demand revenue hcv product change formulary coverage reimbursement level discount rebate offer hcv product payer impact anticipate revenue expect pricing pressure hcv market continue product mature private insurer government payer reduce reimburse patient increase pressure reduce price new brand generic product introduce major market ability maintain pricing market share affect item risk factor substantial portion revenue derive sale product treat hcv hiv unable maintain continue increase sale product result operation adversely affect february receive subpoena attorney office district massachusetts request document relate support c organization provide financial assistance patient hcv product document concern provision financial assistance patient company disclose similar inquiry cooperate inquiry possible action take department justice result civil penalty injunctive relief negative publicity negative action harm reputation reduce demand product andor reduce coverage product include federal health care program medicare medicaid state health care program event occur business stock price materially adversely affect united states healthcare reform legislative regulatory change government prescription drug procurement reimbursement program occur relatively frequently united states foreign jurisdiction unite states pharmaceutical manufacturer brand drug product require pay portion industry fee know brand prescription drug bpd fee calculate base select government sale year percentage total industry government sale annual bpd fee impose pharmaceutical industry billion increase billion increase peak billion decrease billion bpd fee expense million million million bpd fee tax deductible addition discussion continue federal level legislation allow require federal government directly negotiate price concession pharmaceutical manufacturer set minimum requirement medicare price certain state propose legislation seek regulate pharmaceutical drug pricing propose legislation pass experience additional pricing pressure product extensive discussion possible repeal amendment patient protection affordable care act affordable care act government action negatively impact use andor reimbursement product january congress vote adopt budget resolution fiscal year law widely view step passage legislation repeal certain aspect affordable care act january new administration issue executive order direct federal agency authority responsibilitie affordable care act waive defer grant exemption delay implementation provision affordable care act impose fiscal burden state cost fee tax penalty regulatory burden individual healthcare provider health insurer manufacturers pharmaceuticals medical device congress consider legislation replace repeal element affordable care act addition state propose legislation seeks indirectly directly regulate pharmaceutical drug pricing require biopharmaceutical manufacturer publicly report proprietary pricing information place maximum price ceiling pharmaceutical product purchase state agency propose legislation pass experience additional pricing pressure product similar bill previously introduce federal level expect additional legislation introduce year potential effect health insurance market destabilization ongoing repeal replace discussion impact potential change way medicaid program finance likely affect patient source insurance resultant drug coverage discussion continue federal level policy allow require government directly negotiate drug price pharmaceutical manufacturer medicare patient require manufacturer pay high rebate medicare state flexibility drug cover medicaid program policy proposal impact reimbursement product discussion center legislation permit reimportation prescription medication canada country difficult predict impact legislation use reimbursement product united states include potential importation generic version product addition state medicaid program request additional supplemental rebate product result increase federal base medicaid rebate private insurer use enactment increase rebate exert pricing pressure product extent private insurer manage care program follow medicaid coverage payment development adverse effect magnify private insurer adopt low payment schedule health care fraud abuse law antibribery law subject federal state law pertain health care fraud abuse include antikickback law false claim law antikickback law illegal prescription drug manufacturer solicit offer receive pay remuneration exchange induce referral business include purchase prescription particular drug breadth statutory provision increase attention give law enforcement authority possible certain practice challenge antikickback similar law false claim law generally prohibit knowingly present cause present false fraudulent claim payment federal certain state payer include medicare medicaid knowingly make cause false record statement material false fraudulent claim sale marketing patient support medical activity subject scrutiny law addition foreign corrupt practice act similar worldwide antibribery law generally prohibit company intermediary make improper payment purpose obtain retain business policy mandate compliance antibribery law operate part world experience governmental corruption degree certain circumstance strict compliance antibribery law conflict local custom practice require interact doctor hospital state control manner different local custom despite train compliance program internal control policy procedure protect reckless criminal act commit employee agent violation fraud abuse law antibribery law punishable criminal andor civil sanction include fine civil monetary penalty possibility exclusion federal health care program include medicare medicaid violation lead imposition corporate integrity agreement similar government oversight program government allege convict violate law disruption business material adverse effect result operation compulsory license number develop country government official interested group suggest pharmaceutical company drug hcv hiv infection available low cost alternatively government develop country require grant compulsory license allow competitor manufacture sell version product reduce product sale example grow attention availability hcv therapy activist advocate increase availability hcv therapy mean include compulsory license past certain office government brazil express concern affordability hiv product declare consider issue compulsory license permit manufacture patent product hiv infection include viread addition concern cost availability tamiflu relate potential avian flu pandemic hn influenza generate international discussion compulsory licensing tamiflu patent example canadian government consider allow canadian manufacturer manufacture export active ingredient tamiflu eligible develop develop country canada access medicine regime furthermore roche issue voluntary license permit thirdparty manufacturing tamiflu example roche grant sublicense shanghai pharmaceutical group co ltd china sublicense indias hetero drug limited india certain develop country compulsory license permit generic manufacturing override product patent hcv product hiv product tamiflu require grant compulsory license product reduce earning cash flow harm business addition certain country permit enforcement patent permit patent issue thirdparty manufacturer able sell generic version product country example july brazilian patent authority reject patent application tdf active pharmaceutical ingredient viread high level appeal available brazilian patent authority currently patent brazil brazilian government purchase supply tdf generic manufacturer quarter brazilian health regulatory agency reject patent application relate sofosbuvir hcv product plan appeal decision sale generic version product significantly reduce sale adversely affect result operation particularly generic version product import territory exist commercial sale employee january approximately employee believe good relation employee environment health safety strive reduce environmental footprint implement sustainable business process practice incorporate sustainability development distribution medicine safety regulatory compliance product regular efficiency improvement manufacturing process operation surround product portfolio routinely evaluate new innovative way incorporate social environmental responsibility practice include ethical source material green chemistry practice solvent recycling continue improvement sustainability efficiency api product development process gilead site world identify opportunity reduce natural resource usage water conservation sustainable building practice energy conservation recycling diversion landfill alternative transportation continue look way minimize impact environment factor contribute environmental impact include greenhouse gas emission produce employee commute energy water consume facility use hazardous material chemical viruse radioactive compound rd facility refer corporate social responsibility report find website wwwgileadcom responsibility measure take mitigate environmental impact business subject number law regulation require compliance federal state local regulation workplace safety protection environment anticipate additional regulation near future law regulation implement consideration mitigate effect climate change mainly cause greenhouse gas emission business energy intensive anticipate subject cap trade system mitigation measure materially impact capital expenditure operation competitive position base current information subject finalization propose regulation believe primary risk relate climate change increase energy cost information subject information requirement exchange act file periodic report proxy statement information sec report proxy statement information obtain visit public reference room sec f street ne washington dc call sec sec send electronic message sec publicinfosecgov send fax sec addition sec maintain website wwwsecgov contain report proxy information statement information issuer file electronically mail address headquarters lakeside drive foster city california telephone number location website wwwgileadcom link investors section website sec filings financial information section available follow filing soon reasonably practicable electronically file furnished sec annual report quarterly report form q current report form k amendment report file furnish pursuant section exchange act filing available free charge request transaction iran transaction iran require disclosure annual report item risk factor evaluate business carefully consider follow risk addition information annual report manifestation follow risk materially adversely affect business result operation financial condition note factor investor permit private security litigation reform act possible predict identify factor consider follow risk complete statement potential risk uncertainty face substantial portion revenue derive sale product treat hcv hiv unable increase hiv sale hcv sale decrease anticipate result operation adversely affect year end december sale epclusa harvoni sovaldi treatment hcv account approximately total product sale primary driver hcv product revenue patient start follow market share average treatment duration price second quarter number new patient start diminish expect patient start decline relative major market result decline hcv revenue revenue patient decline result increase competition pricing pressure large anticipate shift payer mix highly discount payer segment geographic region decrease average duration treatment few patient treat week patient treat week experience decline market share increase competition new hcv product enter market addition future sale epclusa harvoni sovaldi difficult estimate demand depend extent reimbursement hcv product private government payer light continued financial crisis experience country european union government announce implement measure reduce healthcare expenditure continue experience global pricing pressure result large discount rebate product delay reimbursement negatively impact product sale result operation private public payer choose exclude epclusa harvoni sovaldi formulary coverage list limit type patient coverage provide negatively impact demand revenue epclusa harvoni sovaldi change formulary coverage reimbursement level discount rebate offer hcv product payer impact anticipate revenue expect pricing pressure hcv market continue unable achieve forecasted hcv sale hcv product revenue result operation negatively affect stock price experience significant volatility receive substantial portion revenue sale product treatment hiv infection include descovy odefsey genvoya truvada stribild compleraeviplera atripla year end december sale hiv product account approximately total product sale hiv product contain tenofovir alafenamide taf tenofovir disoproxil fumarate tdf andor emtricitabine belong nucleoside class antiviral therapeutic addition treatment paradigm hiv change cause nucleosidebase therapeutic fall favor unable maintain increase hiv product sale result operation likely suffer likely need scale operation include spend research development rd effort unable sustain increase sale hcv hiv product number reason include limited reason discuss follow hcv hiv product long period time patient combination product additional study conduct new issue respect safety resistance interaction drug arise cause provide additional warning contraindication label narrow approve indication halt sale product reduce revenue product mature private insurer government payer reduce reimburse patient product increase pressure reduce price physician benefit hcv hiv product sale hcv hiv product limit new branded generic product introduce major market ability maintain pricing market share affect example tdf active pharmaceutical ingredient stribild compleraeviplera atripla truvada main active pharmaceutical ingredient viread expect face generic competition united states european union country addition emtricitabine active pharmaceutical ingredient truvada face generic competition european union truvada expect face generic competition european union country outside united states negative impact business result operation fail commercialize new product expand indication exist product prospect future revenue adversely affect introduce new product increase sale exist product able increase maintain total revenue continue expand rd effort drug development inherently risky product candidate fail drug development process example announce terminate phase b study simtuzumab treatment idiopathic pulmonary fibrosis nash primary sclerose cholangitis phase study gs treatment crohns disease ulcerative colitis phase study selonsertib treatment pulmonary arterial hypertension diabetic kidney disease study eleclazine treatment cardiovascular disease addition decide terminate product development expend significant resource effort example completion phase study momelotinib treatment myelofibrosis decide terminate development momelotinib fourth quarter quarter file new drug application nda marketing authorization application maa united states european union approval investigational oncedaily singletablet regimen sofosbuvir mg velpatasvir mg voxilaprevir mg sofvelvox treatment directacting antiviral daaexperience hcvinfected patient future marketing application file approve regulatory authority timely basis marketing approval grant product significant limitation use unable file marketing application new product inability accurately predict demand product uptake new product fluctuation customer inventory make difficult accurately forecast sale cause forecast revenue earning fluctuate adversely affect financial result stock price unable accurately predict demand product include uptake new product demand dependent number factor example hcv product epclusa harvoni sovaldi represent significant change treatment paradigm hcvinfecte patient shorten duration treatment elimination pegylate interferon injection ribavirin patient population product represent cure competitor hcv product enter market continue enter market revenue hcv product difficult investor estimate primary driver hcv product revenue patient start follow market share average treatment duration price experience number patient start difficult accurately predict addition demand epclusa harvoni sovaldi depend extent reimbursement hcv product private public payer united states country private public payer choose exclude epclusa harvoni sovaldi formulary coverage list limit type patient coverage provide negatively impact demand revenue epclusa harvoni sovaldi continue experience pricing pressure united states european union japan country change formulary coverage reimbursement level discount rebate offer hcv product payer negatively impact anticipate revenue addition rebate claim product discount payer quarter arrear estimate rebate require pay connection sale particular quarter base claim datum prior quarter quarter receive higher expect prior quarter rebate claim effect lower revenue quarter hcvrelate revenue difficult predict investor widely vary expectation materially higher low actual anticipate revenue extent actual anticipate hcv product revenue exceed fall short expectation stock price experience significant volatility year end december approximately product sale united states wholesaler mckesson corp amerisourcebergen corp cardinal health inc wholesaler enter inventory management agreement estimate determine end user demand completely effective match inventory level actual end user demand result change inventory level hold wholesaler cause operating result fluctuate unexpectedly sale wholesaler match end user demand addition inventory hold retail pharmacy nonwholesaler location inventory management agreement control buy pattern adverse change economic condition factor cause retail pharmacy reduce inventory product reduce order wholesaler consequently wholesalers order end user demand change example fourth quarter strong wholesaler subwholesaler purchase hiv product result inventory drawdown wholesaler subwholesaler quarter inventory distribution channel fluctuate quarter quarter continue fluctuation earning mismatch prescription demand product revenue addition nonretail sector united states include government institution include state adap va correctional facility large health maintenance organization tend consistent term buy pattern cause quarteroverquarter fluctuation necessarily mirror patient demand product federal state budget pressure include sequestration annual grant cycle federal state fund cause purchasing pattern reflect patient demand product example quarter certain prior year observe large nonretail purchase hiv product number state adap exceed patient demand believe purchase drive grant cycle federal adap fund additionally second half experience fluctuation va new hcv patient start purchase pattern va funding expect continue experience fluctuation purchase pattern nonretail customer result fluctuation product sale revenue earning future light global economic downturn budget crisis face european country observe variation purchase pattern induce cost containment measure europe believe measure cause government agency purchaser reduce inventory product distribution channel decrease revenue cause fluctuation product sale earning continue trend future require pay significant damage merck result jurys finding willfully infringe patent own merck idenix subsidiary december idenix universita degli studi di cagliari udsg centre national de la recherche scientifique luniversit montpellier ii sue district court district delaware allege commercialization sofosbuvir infringe idenixs patent patent interference exist patent patent december idenix udsg sue district court district massachusetts allege commercialization sofosbuvir infringe patent nos patent patent june court transfer massachusetts litigation district court district delaware idenix acquire merck august jury trial hold december patent december jury find willfully infringe assert claim patent award idenix billion past damage party file posttrial motion briefing quarter expect judge rule fourth quarter judge issue ruling case court appeal federal circuit predict certainty ultimate outcome litigation believe jury verdict error error court respect certain ruling trial expect argument forthcome posttrial motion appeal focus argument judge jury properly construe gilead infringe claim patent ii patent invalid failure properly describe claim invention iii patent invalid enable skill art practice claim invention jurys verdict upheld appeal estimate potential loss december include billion determined jury represent adjust revenue sofosbuvir contain product launch august ii approximately million represent adjust revenue sofosbuvir contain product september december iii prejudgment interest iv enhance damage time sum ii result jurys find willfulness v attorney fee estimate range possible loss december zero billion sum exclude immaterial relate prejudgment sale interest january ii go forward royalty assess court estimate time high result jury find willfulness payable base adjusted revenue sofosbuvircontaine product period january expiry idenix patent expect judge rule go forward royalty enhance damage course decide posttrial motion time determine judge case court determination enhance damage appeal jurys verdict upheld appeal require pay material time magnitude payment material adverse impact result operation stock price result operation adversely affect current potential future healthcare reform legislative regulatory change government prescription drug procurement reimbursement program occur relatively frequently united states foreign jurisdiction unite states pharmaceutical manufacturer brand drug product require pay portion industry fee know brand prescription drug bpd fee calculate base select government sale year percentage total industry government sale annual bpd fee impose pharmaceutical industry billion increase billion increase peak billion decrease billion bpd fee expense million million million bpd fee tax deductible extensive discussion possible repeal amendment patient protection affordable care act affordable care act government action negatively impact use andor reimbursement product january congress vote adopt budget resolution fiscal year law widely view step passage legislation repeal certain aspect affordable care act january new administration issue executive order direct federal agency authority responsibilitie affordable care act waive defer grant exemption delay implementation provision affordable care act impose fiscal burden state cost fee tax penalty regulatory burden individual healthcare provider health insurer manufacturers pharmaceuticals medical device congress consider legislation replace repeal element affordable care act addition state propose legislation seeks indirectly directly regulate pharmaceutical drug pricing require biopharmaceutical manufacturer publicly report proprietary pricing information place maximum price ceiling pharmaceutical product purchase state agency propose legislation pass experience additional pricing pressure product similar bill previously introduce federal level expect additional legislation introduce year potential effect health insurance market destabilization ongoing repeal replace discussion impact potential change way medicaid program finance likely affect patient source insurance resultant drug coverage discussion continue federal level policy allow require government directly negotiate drug price pharmaceutical manufacturer medicare patient require manufacturer pay high rebate medicare state flexibility drug cover medicaid program policy proposal impact reimbursement product discussion center legislation permit reimportation prescription medication canada country difficult predict impact legislation use reimbursement product united states include potential importation generic version product addition state medicaid program request additional supplemental rebate product result increase federal base medicaid rebate private insurer use enactment increase rebate exert pricing pressure product extent private insurer manage care program follow medicaid coverage payment development adverse effect magnify private insurer adopt low payment schedule exist product subject reimbursement government agency party pharmaceutical pricing reimbursement pressure reduce profitability successful commercialization product depend availability governmental thirdparty payer reimbursement cost product relate treatment market sell product government health authority private health insurer organization generally provide reimbursement united states european union japan significant potentially significant market product product candidate government authority thirdparty payer increasingly attempt limit regulate price medical product service significant portion sale majority product subject significant discount list price risk factor substantial portion revenue derive sale product treat hcv hiv unable maintain continue increase sale product result operation adversely affect patient assistance program pharmaceutical product come increase scrutiny government legislative body enforcement agency activity result action effect reduce price harm business reputation recently enhance scrutiny companysponsore patient assistance program include insurance premium copay assistance program donation thirdparty charity provide assistance vendor donation recipient deem fail comply relevant law regulation government guidance area subject criminal civil sanction include significant fine civil monetary penalty exclusion participation government healthcare program include medicare medicaid action executive oversee business burdensome remediation measure february receive subpoena attorney office district massachusetts request document relate support c organization provide financial assistance patient hcv product document concern provision financial assistance patient company disclose similar inquiry cooperate inquiry possible action take department justice result inquiry future action take federal local government legislative body enforcement agency result civil penalty injunctive relief negative publicity negative action harm reputation reduce demand product andor reduce coverage product include federal health care program medicare medicaid state health care program event occur business stock price materially adversely affect approximately product sale occur outside united states currency fluctuation hedging expense cause earning fluctuate adversely affect stock price significant percentage product sale denominate foreign currency primarily euro yen face exposure adverse movement foreign currency exchange rate dollar strengthen foreign currency relative value sale respective foreign currency decrease conversely dollar weaken currency relative value sale increase overall net receiver foreign currency benefit weak dollar adversely affect strong dollar use foreign currency exchange forward option contract hedge percentage forecast international sale primarily denominate euro yen hedge certain monetary asset liability denominate foreign currency reduce eliminate exposure currency fluctuation date transaction record date cash collect pay foreign currency exchange net hedge unfavorable impact million product sale compare unfavorable impact million revenue compare predict future fluctuation foreign currency exchange rate dollar dollar appreciate significantly certain currency hedge program sufficiently offset effect appreciation result operation adversely affect stock price decline additionally expense recognize relation hedging activity cause earning fluctuate level hedging expense recognize particular period impact change interest rate spread foreign currency hedge dollar face significant competition face significant competition large global pharmaceutical biotechnology company specialize pharmaceutical firm generic drug manufacturer product compete available product base primarily efficacy safety tolerability acceptance doctor ease patient compliance ease use price insurance reimbursement coverage distribution marketing hcv product epclusa harvoni sovaldi compete viekira pak ombitasvir paritaprevir ritonavir tablet copackage dasabuvir tablet viekira xr dasabuvir ombitasvir paritaprevir ritonavir market abbvie inc abbvie zepatier elbasvir grazoprevir market merck co inc merck daklinza daclastavir market bristolmyer squibb bms olysio simeprevir market janssen therapeutic expect new short duration alloral directacting antiviral product launch competitor negatively impact hcv market share hiv product compete primarily product viiv market fixeddose combination product compete descovy odefsey genvoya stribild compleraeviplera atripla truvada example product market viiv tivicay dolutegravir integrase inhibitor triumeq single tablet triplecombination antiretroviral regimen adversely impact sale hiv product addition lamivudine market viiv compete emtricitabine active pharmaceutical ingredient emtriva component genvoya stribild compleraeviplera atripla truvada tybost compete ritonavir market abbvie face competition generic hiv product generic version lamivudine combivir lamivudine zidovudine available united states certain country generic version sustiva efavirenz component atripla available canada europe anticipate competition generic efavirenz united states december observe pricing pressure relate sustiva component atripla sale tdf active pharmaceutical ingredient stribild compleraeviplera atripla truvada main active pharmaceutical ingredient viread expect face generic competition united states european union country addition emtricitabine active pharmaceutical ingredient truvada face generic competition european union truvada expect face generic competition european union country outside united states hbv product vemlidy viread hepsera face competition baraclude entecavir market bms generic entecavir hbv product compete tyzekasebivo telbivudine market novartis zydelig competes imbruvica ibrutinib market pharmacyclic llc abbvie company gazyva obinutuzumab market genentech member roche group treanda bendamustine hydrochloride market cephalon inc letairis competes tracleer bosentan opsumit macitentan market actelion pharmaceutical inc adcirca tadalafil market united therapeutics corporation pfizer ranexa compete predominantly generic compound distinct class drug treatment chronic angina united states include generic andor brand betablocker calcium channel blocker longacte nitrate cayston compete tobi tobramycin inhalation solution market novartis tamiflu compete relenza zanamivir market gsk product sell generic competitor ambisome compete vfend voriconazole market pfizer caspofungin product develop merck market cancidas united states caspofungin addition aware lipid formulation claim similarity ambisome available outside united states formulation reduce market demand ambisome furthermore manufacture lipid formulation amphotericin b complex formulation find unsafe sale ambisome negatively impact association addition number company pursue development technology competitive exist product research program compete company include specialized pharmaceutical firm large pharmaceutical company act independently pharmaceutical company furthermore academic institution government agency public private organization conduct research seek patent protection establish collaborative arrangement competitive product program competitor gain market share product adversely affect result operation stock price significant safety issue arise market product product candidate future sale reduce adversely affect result operation datum support marketing approval product form basis safety warning product label obtain control clinical trial limit duration case postapproval use product long period time patient underlie health problem take numerous medicine expect continue find new issue safety resistance drug interaction issue require provide additional warning contraindication label narrow approve indication reduce market acceptance product regulatory authority move active transparent pharmacovigilance make great amount standalone safety information clinical trial datum directly available public website mean eg periodic safety update report summarie risk management plan summarie adverse event datum safety information appropriate context expertise misinterpret lead misperception legal action potentially cause product sale stock price decline safety resistance drug interaction issue arise market product sale product limit halt regulatory authority result operation adversely affect operation depend compliance complex fda comparable international regulation failure obtain broad approval timely basis maintain compliance delay halt commercialization product product develop approve marketing sale regulatory authority approve subject extensive regulation fda european medicines agency ema comparable regulatory agency country continue clinical trial product currently approve additional use anticipate file marketing approval additional country additional indication product year product fail receive marketing approval timely basis manufacture sell product subject extensive regulation review discovery previously unknown problem market product problem manufacture safety report promotional activity result restriction product include withdrawal product market fail comply applicable regulatory requirement include related promotion manufacturing subject penalty include fine suspension regulatory approval product recall seizure product criminal prosecution example fda rule require conduct postapproval clinical study assess know risk signal risk identify unexpected risk implement risk evaluation mitigation strategy product include medication guide patient package insert communication plan healthcare provider element fda deem necessary assure safe use drug include impose certain restriction distribution use product failure comply requirement impose sponsor fda result significant civil monetary penalty operating result adversely affect result anticipate timeline clinical trial uncertain support continue development product candidate adversely affect prospect future revenue growth require demonstrate safety efficacy product develop intend use extensive preclinical study clinical trial result preclinical early clinical study accurately predict result later largescale clinical trial successfully complete largescale clinical trial result marketable product example announce terminate phase b study simtuzumab treatment idiopathic pulmonary fibrosis nash primary sclerose cholangitis phase study gs treatment crohns disease ulcerative colitis phase study selonsertib treatment pulmonary arterial hypertension diabetic kidney disease study eleclazine treatment cardiovascular disease determine study datum show insufficient evidence treatment benefit addition completion phase study momelotinib treatment myelofibrosis decide terminate development momelotinib product candidate fails achieve primary endpoint clinical trial safety issue arise result clinical trial inadequate support regulatory approval product candidate commercialization product candidate delay halt addition face challenge clinical trial protocol design clinical trial product candidate pipeline delay terminate prospect future revenue growth adversely impact example face numerous risk uncertaintie product candidate include singletablet regimen bictegravir emtricitabine taf treatment hiv infection descovy prep selonsertib treatment nash idelalisib treatment relapse refractory chronic lymphocytic leukemia gs treatment gastric cancer filgotinib treatment rheumatoid arthritis crohns disease ulcerative colitis currently phase clinical trial prevent completion development product candidate risk include ability enroll patient clinical trial possibility unfavorable result clinical trial need modify delay clinical trial perform additional trial risk fail obtain fda regulatory body approval result product candidate successfully commercialize strategic decision discontinue development product candidate example believe commercialization difficult relative opportunity pipeline program pipeline complete timely basis prospect future revenue growth adversely impact addition clinical trial involve commercial product raise new safety issue exist product turn decrease revenue harm business reliance thirdparty contract research organization conduct clinical trial unable directly control timing conduct expense quality clinical trial extensively outsource clinical trial activity usually perform small portion startup activity inhouse rely independent party contract research organization cro perform clinical study include document preparation site identification screen preparation prestudy visit training program management bioanalytical analysis important aspect service perform cros direct control dispute disruption relationship cro clinical trial delay regulatory submission rely quality validity clinical work perform thirdparty cro cro process methodology result determine invalid inadequate clinical data result relate regulatory approval adversely affect depend relationship company sale marketing performance development commercialization product candidate revenue failure maintain relationship poor performance company dispute company negatively impact business rely number significant collaborative relationship major pharmaceutical company sale marketing performance certain territory include collaboration janssen odefsey compleraeviplera bms atripla united states europe canada f hoffmannla roche ltd hoffmannla roche inc roche tamiflu worldwide gsk ambrisentan territory outside united states country rely international distributor sale truvada viread hepsera emtriva ambisome relationship involve clinical development product partner reliance collaborative relationship pose number risk include risk unable control resource corporate partner devote program product dispute arise respect ownership right technology develop corporate partner disagreement corporate partner cause delay termination research development commercialization product candidate result litigation arbitration contract corporate partner fail provide significant protection fail effectively enforce partner fails perform corporate partner considerable discretion elect pursue development additional product pursue alternative technology product collaboration competitor corporate partner marketing right choose pursue compete technology devote few resource marketing product product development distributor corporate partner unable pay particularly light current economic condition give risk great deal uncertainty success current future collaborative effort effort fail product development commercialization new product delay revenue product decline addition letairis cayston distribute thirdparty specialty pharmacy pharmacie specialize dispense medication complex chronic condition require high level patient education ongoing counseling use specialty pharmacy require significant coordination sale marketing medical affair regulatory affair legal finance organization involve risk include limited risk specialty pharmacy provide accurate timely information inventory patient data safety complaint effectively sell support letairis cayston devote resource necessary sell letairis cayston volume time frame expect able satisfy financial obligation cease operation rely party administer letairis education access program restrict distribution program design support letairis party provide information education prescriber patient risk letairis confirm insurance coverage investigate alternative source reimbursement assistance ensure fulfillment risk management requirement mandate letairis fda coordinates control dispense patient thirdparty specialty pharmacy failure party specialty pharmacy distribute letairis perform expect result regulatory action fda decrease letairis sale harm business success depend significant degree ability defend patent intellectual property right domestically internationally able obtain effective patent protect technology use competitor patent company require stop pay use require technology patent proprietary right important business success depend significant degree ability obtain patent license patent right preserve trade secret defend infringement effort invalidate patent operate infringe intellectual property properly draft enforceable patent difficult competitor use technology create competitive product difficult competitor obtain patent prevent technology create business strategy actively seek patent protection united states internationally file additional patent application appropriate cover improvement compound product technology number foreign patent patent application right patent relate compound product technology certain issue patent enforceable provide adequate protection pende patent application result issue patent patent application confidential period time patent issue result know competitor file patent application technology cover pende application invent file application direct technology subject patent application competitor file patent application receive patent obtain additional patent proprietary right block compete product addition competitor file patent application cover technology participate litigation interference proceeding determine right patent litigation interference proceeding unpredictable expensive ultimately successful result operation adversely affect event example tdf active pharmaceutical ingredient stribild compleraeviplera atripla truvada main active pharmaceutical ingredient viread expect face generic competition united states european union country addition emtricitabine active pharmaceutical ingredient truvada face generic competition european union truvada expect face generic competition european union country outside united states entry generic product lead market share price erosion negative impact business result operation addition patent cover ranolazine compound active ingredient ranexa instead discover sustainedrelease formulation ranolazine achieve therapeutic plasma level patent obtain formulation characteristic plasma level achieve patent cover active ingredient ambisome obtain patent certain product year marketing approval obtain product patent limited life begin run prior commercial sale relate product commercial value patent limit able apply patent term extension supplementary protection certificate country generic manufacturer seek continue seek fda approval market generic version product abbreviate new drug application anda application form typically manufacturer seek approval generic drug description anda litigation note commitment contingency legal proceeding note consolidated financial statement include item annual report risk factor entitle litigation generic manufacturer increase expense continue reduce earning unsuccessful lawsuit claim patent narrow invalidated generic version product launch prior patent expiry begin success depend large ability operate infringe patent proprietary right party infringe valid patent party prevent commercialize product require obtain license party able obtain alternative technology require license reasonable term fail obtain license alternative technology unable develop commercialize product example aware patent relate operation leap restrict distribution program design support letairis aware patent patent application own party claim cover use sofosbuvir aware patent assign department health human service purport claim process protect primate host infection immunodeficiency retrovirus administer combination emtricitabine tenofovir tdf prior exposure host immunodeficiency retrovirus contact department health human service scope relevance patent description litigation sofosbuvir note commitment contingency legal proceeding note consolidated financial statement include item annual report risk factor entitle party successful establish exclusive right epclusa harvoni andor sovaldi expect revenue earning sale product adversely affect beginning furthermore rely unpatented trade secret improvement unpatente internal knowhow technological innovation example great deal liposomal manufacturing expertise key component liposomal technology cover patent instead protect trade secret protect right mainly confidentiality agreement corporate partner employee consultant vendor agreement provide confidential information develop known individual course relationship keep confidential disclose party specify circumstance case employee agreement provide invention individual employ exclusive property certain party comply confidentiality agreement adequate remedy breach trade secret know independently discover competitor rd agreement invention jointly own corporate partner case exclusive property party certain circumstance difficult determine own particular invention dispute arise invention trade secret confidential information know independently discover competitor enter dispute ownership invention business result operation adversely affect party successful establish exclusive right epclusa harvoni andor sovaldi expect revenue earning sale product adversely affect patent patent application claim sofosbuvir sovaldi chemical entity metabolite fixeddose combination ledipasvir sofosbuvir harvoni sofosbuvir velpatasvir epclusa party obtain right patent allegedly prevent attempt prevent commercialize epclusa harvoni sovaldi example aware patent patent application own party allege party cover use epclusa harvoni sovaldi predict ultimate outcome intellectual property claim relate epclusa harvoni sovaldi spend continue spend significant resource defend claim party successfully obtain valid enforceable patent successfully prove infringement patent epclusa harvoni andor sovaldi prevent sell sofosbuvir able obtain license patent license available commercially reasonable term interference proceeding litigation idenix pharmaceuticals inc idenix universita degli studi di cagliari udsg centre national de la recherche scientifique luniversite montpellier ii february receive notice patent trademark office uspto declare interference idenix interference patent patent idenixs pende patent application determine invent certain nucleoside compound january uspto patent trial appeal board ptab determine pharmasset idenix invent compound idenix appeal ptab decision district court district delaware stayed appeal pende outcome appeal interference involve idenixs patent patent describe december receive request uspto declare interference second idenix interference pende patent application idenixs patent patent patent include claim direct method treat hcv nucleoside compound march ptab determine pharmasset idenix invent claim method treat hcv idenix appeal decision district court district delaware court appeal federal circuit cafc cafc hear oral argument september awaiting decision file motion dismiss appeal delaware court stay appeal relate second idenix interference believe idenix claim involve second idenix interference similar foreign patent claim compound metabolite use thereof invalid result file impeachment action federal court canada invalidate idenix canadian patent patent canadian patent correspond patent idenix assert commercialization sovaldi canada infringe patent canadian patent correspond patent invalid november canadian court hold idenixs patent invalid patent valid idenix appeal decision canadian federal court appeal november appeal hearing hold january await decision file similar legal action norway oslo district court seek invalidate idenixs norwegian patent correspond patent september idenix file invalidation action norwegian proceeding norwegian patent correspond patent march norwegian court find claim idenix norwegian patent invalid upheld validity claim patent idenix appeal decision norwegian court appeal april court appeal issue decision invalidate idenix patent uphold patent idenix file appeal january file legal action federal court australia seek invalidate idenixs australian patent correspond patent april idenix assert commercialization sovaldi australia infringe australian patent correspond patent march australian court revoke idenixs australian patent idenix appeal decision appeal hearing hold november await decision march european patent office epo grant idenix european patent patent correspond patent day patent grant file opposition epo seek revoke patent opposition hearing hold february epo rule favor revoke patent idenix appeal march idenix initiate infringement proceeding united kingdom uk germany france allege commercialization sovaldi infringe uk german french counterpart patent trial hold uk october december high court justice england wale uk court invalidate challenge claim patent multiple ground idenix appeal november appeal court affirm uk court decision invalidate idenixs patent march german court dsseldorf determine idenix patent highly likely invalid stay infringement proceeding pende outcome opposition hearing hold epo february idenix appeal decision german court staying proceeding idenixs request french proceeding stay idenix award patent correspond patent japan china risk factor require pay significant damage merck result jurys finding willfully infringe patent own merck idenix subsidiary idenix acquire merck august merck continue pursue idenix claim describe litigation merck august merck contact request pay royalty sale sofosbuvir obtain license patent patent patent patent coown ionis pharmaceuticals inc patent cover compound include relate sofosbuvir file lawsuit august district court northern district california seek declaratory judgment merck patent invalid infringe patent prosecution merck amend patent application attempt cover compound relate sofosbuvir initially march jury determine establish merck patent invalid lack write description lack enablement award merck million damage june court rule favor defense unclean hand determine merck recover damage patent judge determined merck require pay attorney fee exceptional nature case fee owe merck determine court merck file notice appeal court appeal federal circuit court decision defense unclean hand appeal issue relate invalidity merck patent decision defense unclean hand reverse appeal merck patent uphold require pay damage royalty sale sofosbuvircontaine product follow appeal event judge indicate determine royalty necessary conclusion appeal case litigation university minnesota university minnesota university obtain patent patent purport broadly cover nucleosides antiviral anticancer activity august university file lawsuit district court district minnesota allege commercialization sofosbuvircontaine product infringe patent believe patent invalid infringe continue commercialization sofosbuvir european patent claim february party file opposition epo request revocation grant european patent cover sofosbuvir expire october epo uphold validity certain claim sofosbuvir patent anticipate challenger appeal decision favor patent appeal process year january party file opposition epo request revocation grant european patent cover taf expire march party file opposition epo request revocation grant european patent cover cobicistat expire confident strength patent predict ultimate outcome action unsuccessful defend opposition patent claim narrowed revoke patent protection sofosbuvir taf cobicistat europe substantially shorten eliminate entirely patent revoke european patent grant covering compound exclusivity base entirely regulatory exclusivity grant ema sovaldi grant regulatory exclusivity prevent generic sofosbuvir enter european union year follow approval sovaldi january lose exclusivity sovaldi prior expect revenue result operation negatively impact year include succeed year exclusivity lose cause stock price decline manufacturing problem include thirdparty manufacturer corporate partner cause inventory shortage delay product shipment regulatory approval adversely affect result operation order generate revenue product able produce sufficient quantity product satisfy demand product result complex manufacturing process manufacturing process pharmaceutical product highly regulate regulator shut manufacturing facility believe comply regulation product manufacture facility thirdparty manufacturer corporate partner depend party perform manufacturing activity effectively timely basis majority solid dose product addition roche party responsible manufacturing tamiflu thirdparty manufacturer corporate partner subject good manufacturing practice gmp extensive regulation govern manufacturing process stability testing record keep quality standard define fda ema similar regulation effect country thirdparty manufacturer corporate partner independent entity subject unique operational financial risk control thirdparty manufacturer corporate partner fail perform require impair ability deliver product timely basis receive royalty cause delay clinical trial application regulatory approval writeoff cost manufacturing batch fail pass quality inspection meet regulatory approval addition thirdparty manufacturer corporate partner able produce product limit number facility limited manufacturing capacity certain product extent risk materialize affect performance obligation financial result adversely affect manufacturing operation subject routine inspection regulatory agency unable remedy deficiency cite fda inspection currently market product time regulatory approval product development adversely affect risk regulatory agency country marketing application pende undertake similar additional review apply heighten standard review delay regulatory approval product country approval product candidate delay production market product interrupt anticipate revenue stock price adversely affect able obtain material supply necessary conduct clinical trial manufacture sell product limit ability generate revenue need access certain supply product conduct clinical trial manufacture product unable purchase sufficient quantity material find suitable alternate material timely manner development effort product candidate delay ability manufacture product limit limit ability generate revenue supplier key component material name nda maa file fda ema regulatory authority product candidate seek marketing approval significant delay occur qualification new supplier require manufacturer qualified regulatory authority manufacturer continue expend time money effort area production quality control ensure compliance gmp manufacturer subject regular periodic inspection regulatory authority follow initial approval result inspection regulatory authority determine equipment facility laboratory process comply applicable regulation condition product approval regulatory authority suspend manufacturing operation manufacture operation single supplier product suspend unable generate sufficient quantity commercial clinical supply product meet market demand turn decrease revenue harm business addition delivery material supplier interrupt reason unable ship certain product commercial supply supply product development clinical trial addition product material utilize operation facility example manufacture certain drug product intermediate utilize ambisome exclusively facility san dimas california event disaster include earthquake equipment failure difficulty unable replace manufacturing capacity timely manner unable manufacture ambisome meet market need addition depend single supplier amphotericin b active pharmaceutical ingredient ambisome highquality cholesterol manufacture ambisome rely single source active pharmaceutical ingredient find letairis cayston astella llc markets lexiscan united states responsible commercial manufacture supply product united states dependent single supplier active pharmaceutical ingredient lexiscan problem single supplier depend negatively impact development commercialization effort significant portion raw material intermediate manufacture antiviral product supply thirdparty manufacturer corporate partner outside united states result political economic factor specific country region include change interpretation trade regulation compliance requirement tax legislation limit prevent party outside united states supply material adversely affect ability manufacture supply antiviral product meet market need material adverse effect operating result litigation generic manufacturer increase expense continue reduce earning unsuccessful lawsuit claim patent narrow invalidated generic version product launch prior patent expiry approval process product fda grant new chemical entity nce exclusivity period manufacturer application approval generic version product approve generic manufacturer challenge patent protect product grant nce exclusivity year prior end nce exclusivity period generic manufacturer seek continue seek fda approval similar identical drug anda application form typically manufacturer seek approval generic drug seek approval generic version product nce status generic manufacturer submit anda fda year brand product approval sofosbuvir date fall december consequently possible generic manufacturer file anda sofosbuvir december current legal proceeding significance generic manufacturer include apotex june receive notice apotex inc apotex submit abbreviate new drug submission ands health canada request permission manufacture market generic version truvada separate and request permission manufacture market generic version viread notice apotex allege patent associate truvada patent associate viread invalid unenforceable andor infringe apotexs manufacture use sale generic version truvada viread august file lawsuit apotex federal court canada seek order prohibition approval and hear case hold april july court issue order prohibit canadian minister health approving apotexs generic version viread product expiry patent july court decline prohibit approval apotexs generic version truvada product court decision rule validity patent launch apotexs generic version truvada product risk infringement patent include patent unable assert present lawsuit liability damage apotex appeal court decision teva november december august receive notice teva pharmaceutical teva submit and canadian minister health request permission manufacture market generic version truvada atripla viread notice teva allege patent associate truvada atripla viread invalid unenforceable andor infringe tevas manufacture use sale generic version product file lawsuit teva federal court canada seek order prohibition approval application december court issue order prohibit canadian minister health approving tevas generic version viread truvada atripla product expiry patent july teva appeal decision court decision rule validity patent accordingly issue appeal canadian minister health prohibit approve tevas product november teva enter settlement agreement resolve ongoing contested proceeding concern tevas ands generic version truvada atripla viread gilead patent associate truvada atripla viread mylan february receive notice mylan pharmaceuticals inc mylan submit anda fda request permission manufacture market generic version tybost cobicistat notice mylan allege patent cover cobicistat invalid obvious mylan generic product infringe invalid claim march file lawsuit mylan district court district delaware district court northern district west virginia january receive letter mylan notify submit duplicate anda fda product currently evaluate mylan letter trial delaware schedule january patent suit cover tybost list orange book stribild genvoya watson february receive notice watson laboratories inc watson submit anda fda request permission manufacture market generic version letairis notice watson allege patent associate ambrisentan tablet invalid unenforceable andor infringe watson manufacture use sale generic version letairis april file lawsuit watson district court district new jersey january reach agreement watson settle litigation sigmapharm june receive notice sigmapharm laboratory llc sigmapharm submit anda fda request permission manufacture market generic version letairis notice sigmapharm allege patent associate ambrisentan tablet invalid unenforceable andor infringe sigmapharm manufacture use sale generic version letairis june file lawsuit sigmapharm district court district new jersey infringement patent date trial sigmapharm set estimate occur second quarter predict ultimate outcome forego action litigation generic manufacturer spend significant resource enforce defend patent unsuccessful lawsuit original claim patent narrow invalidated patent protection truvada viread letairis united states atripla truvada viread canada substantially shorten patent cover product invalidate fda canadian minister health approve request manufacture generic version products united states canada respectively prior expiration date patent sale generic version product early patent expiration significant negative effect revenue result operation face credit risk emerge market southern european customer adversely affect result operation exposure customer credit risk emerge market southern europe southern european product sale governmentowne support customer southern europe specifically spain italy portugal greece historically subject significant payment delay government funding reimbursement practice result continue result day sale outstanding significantly high country average length time account receivable remain outstanding december account receivable net southern europe specifically greece italy portugal spain total approximately million million great day past include million great day past historically receivable balance certain publiclyowne hospital accumulate period time subsequently settle large lump sum payment pattern experience pharmaceutical company sell directly hospital significant change occur reimbursement practice european government government funding unavailable able collect amount customer result operation adversely affect import country product available low price counterfeit version product negative impact reputation business price product base local market economic competition differ country country sale country relatively high price reduce product import country low price market case pharmaceutical product sell steeply discount price develop world reexporte european country resold high price happen product particularly truvada viread agree available substantially reduce price country participate gilead access program atripla complera merck janssen respectively distribute substantially reduce price hiv infect patient develop country revenue adversely affect addition establish partnership india base generic manufacturer distribute generic version tenofovir disoproxil fumarate taf develop world country include india expand agreement include right stribild tybost vitekta enter agreement certain indiabase generic manufacturer produce distribute generic emtricitabine develop world include singletablet regimen contain emtricitabine fixeddose combination emtricitabine coformulate hiv medicine starting enter licensing agreement indiabase generic manufacturer produce distribute generic version hcv product develop country generic version hiv hcv product license export united states europe market outside develop world country revenue adversely affect hcv product available low middleincome country significantly discount price discount hcv product reexporte low middleincome country united states high price market revenue adversely affect addition purchase product country sell price relatively low resale country sell price relatively high adversely impact revenue gross margin cause sale fluctuate quarter quarter example european union require permit product purchase country sell country purchase product country sell price relatively low resale country sell price relatively high affect inventory level hold wholesaler cause relative sale level country fluctuate quarter quarter reflect actual consumer demand give quarter quarterly fluctuation impact earning adversely affect stock price harm business party illegally distribute sell counterfeit version product meet rigorous quality standard manufacturing supply chain example quarter bottle counterfeit drug label harvoni brand discover retail pharmacy chain pharmaceutical wholesaler japan investigate matter cooperate japanese health ministry order help prevent similar issue japan accelerate planned change product packaging counterfeiting difficult actively action discourage counterfeit product world include work local regulatory legal authority enforce law counterfeit drug counterfeit drug pose risk patient health safety reputation business suffer result counterfeit drug sell brand expensive litigation government investigation increase expense continue reduce earning involve number litigation investigation disputerelate matter require expend substantial internal financial resource expect matter continue require high level internal financial resource foreseeable future matter reduce continue reduce earning description litigation investigation disputerelate matter note commitment contingency legal proceeding note consolidated financial statement include item annual report outcome lawsuit lawsuit brought investigation investigation initiate inherently uncertain adverse development outcome result significant expense monetary damage penalty injunctive relief significantly reduce earning cash flow harm business country require grant compulsory license product patent enforce number develop country government official interested group suggest pharmaceutical company drug hcv hiv infection available low cost alternatively government develop country require grant compulsory license allow competitor manufacture sell version product reduce product sale example grow attention availability hcv therapy activist advocate increase availability hcv therapy mean include compulsory license past certain office government brazil express concern affordability hiv product declare consider issue compulsory license permit manufacture patent product hiv infection include viread addition concern cost availability tamiflu relate potential avian flu pandemic hn influenza generate international discussion compulsory licensing tamiflu patent example canadian government consider allow canadian manufacturer manufacture export active ingredient tamiflu eligible develop develop country canada access medicine regime furthermore roche issue voluntary license permit thirdparty manufacturing tamiflu example roche grant sublicense shanghai pharmaceutical group co ltd china sublicense indias hetero drug limited india certain develop country compulsory license permit generic manufacturing override product patent hcv hiv product require grant compulsory license product reduce earning cash flow harm business addition certain country permit enforcement patent permit patent issue thirdparty manufacturer able sell generic version product country example july brazilian patent authority reject patent application tenofovir disoproxil fumarate active pharmaceutical ingredient viread high level appeal available brazilian patent authority currently patent brazil brazilian government purchase supply tenofovir disoproxil fumarate generic manufacturer quarter brazilian health regulatory agency reject patent application relate sofosbuvir hcv product plan appeal decision sale generic version product significantly reduce sale adversely affect result operation particularly generic version product import territory exist commercial sale face significant liability result product cover insurance liability materially reduce earning testing manufacturing marketing use commercial product product candidate development involve substantial risk product liability claim claim directly consumer healthcare provider pharmaceutical company unable maintain sufficient insurance coverage product liability arise addition cost defend lawsuit pay damage product liability claim exceed insurance coverage unable maintain adequate coverage claim exceed coverage financial condition ability clinically test product candidate market product adversely affect addition negative publicity associate claim regardless merit decrease future demand product impair financial condition business disruption natural manmade disaster harm future revenue worldwide operation subject business interruption stem natural manmade disaster selfinsure corporate headquarters fremont location house majority rd activity san dima oceanside manufacture facility locate california seismically active region carry adequate earthquake insurance significant recovery time require resume operation financial condition operating result materially adversely affect event major earthquake dependent information technology system infrastructure datum dependent information technology system infrastructure datum multitude complexity computer system inherently vulnerable service interruption destruction malicious intrusion random attack likewise datum privacy security breach employee pose risk sensitive datum include intellectual property trade secret personal information employee patient customer business partner expose unauthorized person public cyberattack increase frequency sophistication intensity cyberattack include deployment harmful malware denialofservice social engineering mean affect service reliability threaten datum confidentiality integrity availability business partner face similar risk security breach system adversely affect security posture invest continue invest protection datum information technology infrastructure assurance effort prevent service interruption identify breach system adversely affect business operation andor result loss critical sensitive information result financial legal business reputational harm addition liability insurance sufficient type cover claim relate security breach cyberattack relate breach change effective income tax rate reduce earning subject income taxis unite states foreign jurisdiction include ireland economic political condition country actively consider change exist tax law predict form time potential legislative change material adverse impact result operation addition significant judgment require determine worldwide provision income taxis factor favorable unfavorable effect income tax rate include limited change forecast demand hcv product portion nontax deductible annual bpd fee accounting stock option sharebase award merger acquisition ability manufacture product cork ireland facility amortization certain acquisition relate intangible receive tax benefit future level rd spending change mix earning tax jurisdiction operate change overall level pretax earning resolution federal state foreign income tax audits impact income tax provision result mention factor significant negative impact consolidate result operation income tax return subject audit federal state foreign tax authority currently examination internal revenue service tax year state foreign jurisdiction differ interpretation tax law regulation result significant dispute arise tax authority involve issue time deduction allocation income tax jurisdiction resolution exposure report period material impact result operation period fail attract retain highly qualified personnel unable successfully develop new product candidate conduct clinical trial commercialize product candidate future success depend large continue ability attract retain highly qualified scientific technical management personnel personnel expertise clinical testing governmental regulation commercialization face competition personnel company university public private research institution government entity organization competition qualified personnel biopharmaceutical field intense limited pool qualified potential employee recruit able attract retain quality personnel acceptable term unsuccessful recruitment retention effort business harm assurance pay dividend continue repurchase stock board director authorize dividend program intend pay quarterly dividend share subject quarterly declaration board director board director approve repurchase billion common stock billion available repurchase december future declaration time dividend andor time stock repurchase subject capital availability determination board director cash dividend andor stock repurchase good interest stockholder compliance respective law agreement applicable declaration payment cash dividend repurchase stock ability pay dividend andor repurchase stock depend factor cash balance potential future capital requirement strategic transaction include acquisition debt service requirement result operation financial condition factor control board director deem relevant reduction elimination dividend payment dividend program andor stock repurchase negative effect stock price item b unresolved staff comment applicable item property corporate headquarters locate foster city california house administrative manufacturing rd activity rd facility oceanside california fremont california seattle washington alberta canada manufacturing facilities san dimas california oceanside california alberta canada cork ireland global operation include office europe north america asia south america africa australia india middle east believe exist property include own lease site good condition suitable conduct business believe capital resource sufficient purchase lease construct additional facility require meet expect longterm growth need item legal proceeding description significant pende legal proceeding note commitment contingency legal proceeding note consolidated financial statement include item annual report incorporate reference item safety disclosure applicable ii item market registrant common equity relate stockholder matter issuer purchase equity security common stock trade nasdaq global select market symbol gild follow table set forth high low intraday sale price share common stock nasdaq global select market period indicate price represent quotation dealer adjustment retail markup markdown commission represent price actual transaction high low high low quarter second quarter quarter fourth quarter february share common stock outstanding hold approximately stockholder record include share hold broker bank nominee dividend declare pay quarterly cash dividend aggregate billion common share initiate quarterly cash dividend share begin second quarter declare pay aggregate billion common share note stockholder equity note consolidated financial statement include item annual report additional information performance graph follow graph compare cumulative total stockholder return past year index standard poor stock index label sp index nasdaq biotechnology index label nbi index stockholder return show graph necessarily indicative future performance endorse prediction future stockholder return comparison cumulative total return investment past year note section solicit material deem file sec incorporate reference filing securities act exchange act date hereof irrespective general incorporation language filing show cumulative return investment assume investment common stock nbi index sp index december dividend reinveste issuer purchase equity security repurchase million share common stock aggregate purchase price billion billion accelerate stock repurchase program billion open market transaction february board director authorize billion share repurchase program program repurchase open market privately negotiate transaction start repurchase program april table summarize stock repurchase activity program month end december maximum fair total number value share total number average share purchase share price pay publicly purchase purchase share announce program program thousand dollar thousand million october october november november december december total note difference total number share purchase total number share purchase publicly announce program share common stock withhold employee restrict stock award order satisfy applicable tax withholding obligation item select financial datum gilead sciences inc select consolidated financial datum million share datum year end december consolidated statement income datum total revenue total cost expense income operation provision income taxis net income net income attributable gilead net income share attributable gilead common stockholder basic share share calculation basic net income share attributable gilead common stockholder dilute share share calculation dilute cash dividend declare share december consolidated balance sheet datum cash cash equivalent marketable security work capital total asset longterm obligation longterm debt include current portion retain earning total stockholder equity note management discussion analysis financial condition result operation include item annual report description result operation issue billion principal senior unsecured note register offering repay million principal balance convertible senior note million principal balance senior unsecured note december issue billion principal senior unsecured note register offering repay million principal balance convertible senior note issue billion principal senior unsecured note register offering repay million principal balance convertible senior note million principal balance senior unsecured note december million fiveyear revolve credit facility agreement repay billion principal balance convertible senior note repay million fiveyear revolve credit facility agreement complete acquisition pharmasset inc recognize consideration transfer billion primarily record intangible asset net finance transaction approximately billion cash hand billion bank debt issue january billion senior unsecured note issue december retrospectively adopt accounting standard update simplifying presentation debt issuance cost require presentation debt issuance cost direct deduction carrying recognize debt liability balance sheet result reclassify unamortized debt issuance cost asset longterm debt include current portion year present item management discussion analysis financial condition result operation follow management discussion analysis financial condition result operation mda intend help reader understand result operation financial condition mda provide supplement read conjunction audit consolidated financial statement accompany note consolidated financial statement disclosure include item annual report include disclosure item risk factor consolidate financial statement prepare accordance generally accept accounting principle present dollar management overview gilead sciences inc gilead incorporate delaware june researchbase biopharmaceutical company discover develop commercialize innovative medicine area unmet medical need new discovery investigational drug candidate strive transform simplify care people lifethreatene illness world operation country worldwide headquarters foster city california gileads primary area focus include human immunodeficiency virus hiv liver disease chronic hepatitis c virus hcv infection chronic hepatitis b virus hbv infection hematologyoncology cardiovascular inflammationrespiratory disease seek add exist portfolio product internal discovery clinical development program product acquisition inlicense strategy portfolio market product include ambisome atripla cayston compleraeviplera descovy emtriva epclusa genvoya harvoni hepsera letairis odefsey ranexa sovaldi stribild truvada tybost vemlidy viread vitekta zydelig international commercial sale operation marketing subsidiary country sell distribute certain product corporate partner royaltypaye collaborative agreement business highlight continue advance product pipeline therapeutic area goal deliver bestinclass drug advance current standard care andor address unmet medical need highlight activity include submission marketing authorization application oncedaily singletablet regimen sofosbuvir mg velpatasvir mg voxilaprevir mg treatment hcvinfecte patient food drug administration fda european commission fda japanese ministry health labour welfare mhlw approval vemlidy oncedaily treatment adult hbv infection compensate liver disease european commission approval marketing authorization oncedaily truvada combination safersex practice reduce risk sexually acquire hiv infection uninfected adult high risk strategy know preexposure prophylaxis prep fda european commission approval epclusa alloral pangenotypic singletablet regimen treatment adult genotype chronic hcv infection fda european commission approval tenofovir alafenamide tafbase regimen odefsey descovy fixeddose combination treatment hiv infection purchase nimbus apollo inc nimbus whollyowne subsidiary nimbus therapeutic acetylcoa carboxylase acc inhibitor program nimbus program include lead candidate ndi acc inhibitor preclinical acc inhibitor potential treatment non alcoholic steatohepatitis nash hepatocellular carcinoma disease close license collaboration agreement galapagos nv galapagos clinicalstage biotechnology company base belgium development commercialization filgotinib jakselective inhibitor investigate inflammatory disease indication financial highlight total revenue decrease billion total product sale decrease billion compare billion billion respectively primarily low sale harvoni sovaldi partially offset sale epclusa tafbase product genvoya descovy odefsey united states product sale billion compare billion europe product sale billion compare billion japan product sale billion compare billion sale international location billion compare billion research development rd expense increase billion compare primarily overall progression clinical study include ongoing milestone payment purchase fda priority review voucher upfront collaboration expense relate license collaboration agreement galapago purchase nimbus addition record inprocess rd iprd impairment charge relate momelotinib simtuzumab sell general administrative sga expense billion decline brand prescription drug bpd fee expense offset high cost support new product launch geographic expansion net income attributable gilead billion diluted share compare billion diluted share primarily low product sale high rd expense yearoveryear earning share favorably impact share repurchase activity repurchase total million share billion million share billion repurchase accelerate stock repurchase program december billion cash cash equivalent marketable security compare billion december increase primarily issuance billion aggregate principal senior unsecured note september note generate billion operate cash flow utilize billion repurchase stock pay cash dividend billion outlook continue maintain strong operate financial discipline rd perspective continue invest conduct new ongoing clinical study support exist product product candidate expect forward number latestage clinical study new product candidate include progress phase study selonsertib nash order develop product pipeline focus leverage capital pursue external licensing acquisition opportunity fit longterm strategic plan commercial perspective continue focus support uptake recently launch tafbase regimen continue promote use exist commercial product hire fieldbased team promote truvada prep believe continue integral growth hiv united states community embrace public health benefit prevention hcv difficult accurately predict revenue hcv cure market expect patient start decline relative major market primary driver expect decline total product sale expect product sale impact effect competition market share net price continue decrease average duration treatment few patient treat week patient treat week anticipate hcv revenue decline prior year level patient treat expect hcv product generate significant revenue cash flow future continue focus help hcv patient diagnose treater care addition continue invest strategically selectively educational program raise awareness access medication continue focus ensure patient access product world progress initiative subject number uncertainty include limited continuation uncertain global macroeconomic environment additional pricing pressure payer competitor slow anticipate growth hiv franchise increase discount chargeback rebate ongoing contract future negotiation commercial government payer market share price erosion cause introduction generic version truvada outside united states viread later inaccuracy hcv patient start estimate potential amendment affordable care act government action effect lower price large anticipate shift payer mix highly discount payer segment volatility foreign currency exchange rate result operation total revenue follow table summarize period period change product sale royalty contract revenue million percentage change change revenue product sale royalty contract revenue total revenue product sale compare total product sale billion compare billion primarily decrease antiviral product sale antiviral product sale include sale hiv antiviral product hcv product billion compare billion hiv antiviral product sale billion compare billion increase primarily drive continued uptake tafbase product genvoya descovy odefsey partially offset decrease sale tenofovir disoproxil tdfbase product hcv product sale consist harvoni sovaldi epclusa billion compare billion decline low sale harvoni sovaldi partially offset sale epclusa launch location product sale include sale letairis ranexa ambisome billion increase compare billion product sale generate outside united states face exposure movement foreign currency exchange rate primarily euro yen foreign currency exchange contract hedge percentage foreign currency exposure foreign currency exchange net hedge unfavorable impact million product sale compare record product sale net estimate mandatory supplemental discount government payer addition discount private payer include rebate chargeback cash discount prompt payment distributor fee relate cost deduction generally refer grossto net deduction total billion gross product sale compare billion billion billion gross product sale relate government rebate chargeback billion relate cash discount prompt payment distributor fee relate cost increase grosstonet deduction primarily increase discount high percentage sale deeply discount segment hcv product united states product sale united states decrease billion compare billion decline sale hcv product partially offset increase sale hiv antiviral product increase sale hiv antiviral product primarily drive sale newly launch tafbase product favorable revision rebate reserve million primarily relate tdfbase product product sale europe decrease billion compare billion primarily lower harvoni sovaldi sale volume foreign currency exchange net hedge unfavorable impact million product sale compare product sale japan consist sovaldi harvoni increase billion compare billion increase primarily drive high sale volume harvoni launch september partially offset mandatory price reduction sovaldi harvoni effective april product sale international location increase billion compare billion primarily drive continue launch hcv tafbase product location compare total product sale billion compare billion primarily drive increase antiviral product sale antiviral product sale billion compare billion increase primarily drive launch harvoni geography partially offset decline sovaldi sale patient prescribe harvoni instead sovaldi hiv product contribute sale increase primarily increase sale new hiv singletablet regimen stribild compleraeviplera genvoya partially offset decline atripla sale volume product sale include sale letairis ranexa ambisome zydelig billion increase compare billion product sale generate outside united states foreign currency exchange net hedge unfavorable impact million product sale compare grosstonet deduction total billion compare billion billion billion gross product sale relate government rebate chargeback billion relate cash discount prompt payment distributor fee relate cost grosstonet deduction attributable hcv product sale exceed overall grosstonet order obtain formulary status expand access patient product sale united states increase billion compare billion primarily sale harvoni increase sale stribild truvada complera partially offset decline sale sovaldi product sale europe increase billion compare billion primarily sale harvoni foreign currency exchange net hedge unfavorable impact million product sale compare product sale international location increase billion compare billion primarily launch japan sovaldi harvoni september follow table summarize period period change product sale million percentage change change antiviral product hcv product harvoni sovaldi epclusa hiv antiviral product truvada atripla stribild genvoya compleraeviplera viread odefsey descovy antiviral total antiviral product product letairis ranexa ambisome zydelig total product sale percentage meaningful follow additional discussion result product harvoni harvoni approve fda october european commission november japanese mhlw july harvoni sale account total antiviral product sale respectively product sale billion united states billion europe billion japan million international location product sale billion united states billion europe billion japan million international location product sale billion united states million europe united states decrease compare primarily low sale volume low average net selling price partially offset favorable revision sale return reserve million record second quarter number patient start treatment harvoni united states peak half warehoused patient initiate treatment product launch europe decrease compare primarily low sale volume unfavorable foreign currency exchange net hedge japan increase compare drive high sale volume partially offset mandatory price reduction effective april international location decrease compare primarily low average net selling price partially offset continue launch harvoni location increase product sale compare primarily launch harvoni united states europe japan sovaldi sovaldi approve fda december european commission january japanese mhlw march sovaldi sale account total antiviral product sale respectively product sale billion united states million europe million japan million international location product sale billion united states billion europe million japan million international location product sale billion united states billion europe million international location united states decrease compare primarily low sale volume partially offset favorable revision sale return reserve million record second quarter europe decrease compare primarily low sale volume japan decrease compare primarily mandatory price reduction effective april low sale volume international location increase compare primarily drive high sale volume decrease product sale compare primarily volume decline united states patient prescribe harvoni instead sovaldi partially offset volume increase japan europe launch sovaldi epclusa epclusa launch united states europe june july respectively account total antiviral product sale product sale billion primarily drive sale united states billion truvada truvada sale account total antiviral product sale respectively product sale billion united states million europe million international location product sale billion united states billion europe million international location product sale billion united states billion europe million international location truvada sales increase billion compare billion primarily high average net selling price high sale volume united states result increase usage truvada prep truvada sale increase compare billion primarily sale volume growth increase average net selling price united states atripla atripla sale account total antiviral product sale respectively product sale billion united states million europe million international location product sale billion united states million europe million international location product sale billion united states million europe million international location atripla sale decrease billion compare billion compare billion primarily decline sale volume doctor prescribe new regimen include tdf tafbase regimen efavirenz component atripla gross margin zero comprise million billion billion atripla sale respectively generic version bristolmyer squibb company sustiva efavirenz available canada europe available united states observe pricing pressure relate efavirenz component atripla sale observe meaningful splitting atripla singletablet regimen stribild stribild sale account total antiviral product sale respectively product sale billion united states million europe product sale billion united states million europe product sale billion united states million europe stribild sale increase billion compare billion primarily favorable revision rebate reserve million quarter partially offset low sale volume result continued launch new tafbase product genvoya stribild sale increase compare billion primarily high sale volume united states europe tafbase regimen genvoya descovy odefsey genvoya launch united states europe november descovy launch united states europe april odefsey launch united states march launch europe july newly launch tafbase regimen account total antiviral product sale product sale tafbase regimen billion primarily drive sale united states billion compleraeviplera compleraeviplera sale account total antiviral product sale product sale million united states million europe product sale million united states million europe product sale million united states million europe compleraeviplera sale increase billion compare billion primarily favorable revision rebate reserve million quarter compleraeviplera increase compare billion drive primarily high sale volume united states europe royalty contract revenue follow table summarize period period change royalty contract revenue million percentage change change royalty contract revenue royalty contract revenue decline million compare million increase compare million change primarily royalty revenue f hoffmanla roche ltd sales tamiflu majority royalty recognize quarter follow quarter correspond product sale occur cost good sell product gross margin follow table summarize period period change product sale cost good sell product gross margin million percentage change change total product sale cost good sell product gross margin product gross margin decrease compare primarily change product mix hcv product sale decrease percentage total product sale product gross margin increase compare primarily change product mix atripla sale include efavirenz component gross margin zero decline hcv product sale increase percentage total product sale research development expense follow table summarize period period change rd expense million percentage change change rd expense rd expense summarize consist primarily clinical study perform contract research organization material supply license fee upfront payment collaboration agreement milestone payment personnel cost include salary benefit stockbase compensation overhead allocation consist support facilitiesrelate cost track total rd expense product candidate therapeutic area development phase manage rd expense identify rd activity anticipate perform give period prioritize effort base scientific datum probability successful development market potential available human capital resource consideration continually review rd pipeline status development necessary reallocate resource rd portfolio believe good support future growth business follow table provide breakout rd expense major cost type million percentage clinical study outside service personnel infrastructure expense facility cost iprd impairment charge total rd expense increase billion compare primarily increase clinical study outside service expense billion increase clinical study outside service primarily overall progression clinical study include ongoing milestone payment purchase fda priority review voucher upfront collaboration expense relate license collaboration agreement galapago purchase nimbus iprd impairment charge result termination clinical development momelotinib simtuzumab rd expense increase million compare primarily increase personnel infrastructure expense million facility cost million support ongoing clinical study activity geographic expansion clinical study outside service include expense million collaboration acquisition relate expense purchase fda priority review voucher sell general administrative expense follow table summarize period period change sga expense million percentage change change sga expense sga expense relate sale marketing finance human resource legal administrative activity expense primarily comprise facility overhead cost outside marketing advertising legal expense general administrative cost sga expense include bpd fee united states pharmaceutical manufacturer brand drug product require pay portion industry fee bpd fee estimate base select government sale calendar year percentage total industry government sale truedup receipt invoice internal revenue service irs annual bpd fee impose pharmaceutical industry billion increase billion sga expense flat compare decline bpd fee offset high cost support new product launch geographic expansion bpd fee favorably impact credit million base receipt irs invoice sga expense increase million compare primarily increase million headcountrelate marketing expense support growth geographic expansion business partially offset decrease bpd fee million base receipt irs invoice bpd fee expense million million million bpd fee tax deductible interest expense interest expense increase million compare million primarily issuance billion aggregate principal note billion aggregate principal senior unsecured note note interest expense increase million compare million primarily issuance note issuance billion aggregate principal senior unsecured note income expense net income expense net million million million respectively primarily cash cash equivalent marketable security earn high yield provision income taxis provision income tax billion billion billion respectively effective tax rate respectively differ federal statutory rate primarily earning nonus subsidiary operate jurisdiction low tax rate united states earning consider indefinitely reinveste liquidity capital resource believe exist capital resource supplement cash flow generate operating activity adequate satisfy capital need foreseeable future follow table summarize cash cash equivalent marketable security work capital million december cash cash equivalent marketable security work capital cash cash equivalent marketable security cash cash equivalent marketable security total billion december increase billion compare billion december generate billion operate cash flow receive billion net proceed note utilize billion repurchase stock repay million principal balance senior note convertible senior note pay cash dividend billion cash cash equivalent marketable security total billion december increase billion compare billion december generate billion operate cash flow receive billion net proceed issuance senior unsecured note utilize billion repurchase stock utilize billion settle million warrant relate convertible senior note convertible note pay cash dividend billion total cash cash equivalent marketable security december approximately billion generate operation foreign jurisdiction intend use foreign operation rely unrepatriate earning source fund domestic business expect sufficient cash flow borrowing capacity united states fund domestic operational strategic need work capital work capital billion december decrease billion work capital december primarily decline cash cash equivalent result increase longterm marketable security work capital billion december increase billion work capital december drive primarily increase cash cash equivalent shortterm marketable security increase account receivable partially offset increase accrue government rebate cash flow follow table summarize cash flow activity million cash provide operating activity invest activity financing activity cash provide operating activity cash provide operating activity represent cash receipt disbursement related activity invest financing activity operate cash flow derive adjust net income noncash item change operate asset liability cash provide operating activity decrease billion billion compare primarily low cash receipt result low product sale high cash payment relate accrued government rebate chargeback cash flow operation decrease future hcv product sale expect decline cash provide operating activity increase billion billion compare primarily high cash receipt result high product sale cash investing activity cash investing activity primarily consist net purchase marketable security investment capital expenditure cash investing activity decrease million billion compare primarily low net purchase marketable security partially offset investment relate license collaboration agreement galapago cash investing activity increase billion billion compare primarily high net purchase marketable security cash financing activity cash financing activity increase billion billion compare primarily high repurchase common stock high net payment debt high payment cash dividend low proceed issuance debt increase partially offset low payment settle warrant relate convertible note cash financing activity increase billion billion compare primarily high repurchase common stock payment cash dividend begin increase partially offset low net payment debt high proceed issuance debt debt credit facility longterm obligation summary borrowing financing arrangement include note debt credit facility note consolidated financial statement include item annual report debt financing september issue note aggregate principal billion december repay million principal balance relate senior unsecured note september issue note aggregate principal billion intend use net proceed note note general corporate purpose include repayment debt work capital payment cash dividend repurchase outstanding common stock pursuant authorize share repurchase program future acquisition require comply certain covenant note indentures december violation covenant convertible note repayment warrant settlement convertible note partially convert remainder mature repay aggregate principal balance million million respectively pay cash million million respectively relate conversion spread convertible note receive million million cash respectively convertible note hedge relate convertible note portion warrant relate convertible note modify settle august remainder expire pay million billion respectively settle warrant average market price common stock exceed warrant exercise price credit facility terminate exist revolve credit facility enter new billion fiveyear revolve credit facility mature facility work capital requirement general corporate purpose include limitation acquisition require comply certain covenant credit agreement december violation covenant amount outstanding revolve credit facility capital return program stock repurchase programs february board director authorize billion stock repurchase program program purchase program open market privately negotiate transaction program commence billion stock repurchase program authorize board director january complete second quarter billion stock repurchase program authorize board director complete quarter billion repurchase program authorize board director january complete december remain authorize repurchase program billion follow table summarize stock repurchase abovedescribe program million share repurchase retire dividend february announce board director declare quarterly cash dividend share common stock payment date march stockholders record close business march april announce board director declare quarterly cash dividend common share effective second quarter declare pay quarterly cash dividend aggregate billion common share second quarter initiate cash dividend common share declare pay quarterly cash dividend aggregate billion share capital resource believe exist capital resource supplement cash flow generate operation adequate satisfy capital need foreseeable future future capital requirement depend factor include limited follow commercial performance current future product progress scope rd effort include preclinical study clinical trial cost timing outcome regulatory review expansion sale marketing capability possibility acquire additional manufacturing capability office facility possibility acquire company new product debt service requirement establishment additional collaborative relationship company cost associate defense settlement adverse result government investigation litigation include matter relate sofosbuvir future require additional funding form proceed equity debt financing fund require guarantee available favorable term critical accounting policy estimate judgment discussion analysis financial condition result operation base consolidated financial statement include item annual report prepare accordance generally accept accounting principle preparation financial statement require estimate judgment affect report amount asset liability revenue expense related disclosure ongoing basis evaluate base estimate historical experience market specific relevant assumption believe reasonable circumstance result form basis make judgment carry value asset liability readily apparent source actual result differ significantly estimate believe follow critical accounting policy reflect significant judgment estimate preparation consolidated financial statement revenue recognition product sale recognize revenue product sale persuasive evidence arrangement exist delivery occur price fix determinable collectability reasonably assure record product sale net estimate mandatory supplemental discount government payer addition discount private payer relate charge generally refer grosstonet deduction record period relate sale occur government rebate chargeback represent majority grosstonet deduction require complex significant judgment management estimate assess period update reflect current information government rebate chargeback government rebate chargeback include amount pay payer healthcare providers united states include medicaid rebate aid drug assistance program veterans administration public health service discount rebate foreign government rebate rebate chargeback base contractual arrangement statutory requirement vary product payer individual payer plan qualified program purchase product wholesaler distributor low contractual price wholesaler distributor charge difference acquisition cost low contractual price consolidate allowance government chargeback payable direct customer classify reduction account receivable total million december million december consolidated allowance government rebate pay party direct customer record accrue government rebate consolidated balance sheet total billion december billion december allowance government rebate chargeback estimate base product sell historical utilization rate pertinent thirdparty industry information estimate patient population know market event trend channel inventory datum andor market datum consider new information change program regulation guideline impact actual rebate andor expectation future utilization rate program believe methodology use estimate government rebate chargeback reasonable appropriate give current fact circumstance actual result differ significantly estimate year actual government rebate chargeback claim prior period vary estimate follow table summarize consolidated activity end balance government rebate chargeback account million balance decreaseincrease balance end accrue government rebate chargeback begin year product sale payment year year end december activity relate sale activity relate sale prior total year end december activity relate sale activity relate sale prior total majority increase allowance government rebate chargeback compare drive high rebate chargebacks hcv product legal contingency party legal action significant describe note commitment contingency legal proceeding note consolidated financial statement include item annual report possible determine outcome matter recognize accrual action extent conclude loss probable reasonably estimable accrue good estimate loss range estimate range well accrue minimum range determine loss reasonably possible loss range loss estimate disclose possible loss significant judgment require determination probability determination exposure reasonably estimable inherent uncertainty unpredictability relate matter accrual base believe good information available time assessment include legal fact circumstance case status proceeding applicable law view legal counsel final resolution matter possible loss excess record amount material adverse effect result operation cash flow financial position periodically reassess matter additional information available adjust estimate assumption fact circumstance indicate need change recognize accrual matter december believe loss probable valuation intangible asset conjunction business combination record intangible asset primarily relate iprd project total intangible asset billion december billion december identifiable intangible asset measure respective fair value acquisition date model value intangible asset require use significant estimate assumption include limited estimate revenue operate profit relate product product candidate probability success unapproved product candidate consider stage development time resource need complete development approval product candidate life potential commercialize product associate risk include inherent difficulty uncertaintie develop product candidate obtain fda regulatory approval risk relate viability potential alternative treatment future target market believe fair value record intangible asset acquire connection business combination base reasonable estimate assumption give fact circumstance relate valuation date intangible asset relate iprd project consider indefinitelive completion abandonment associate rd effort development complete generally occur regulatory approval market product obtain associate asset deem finitelived amortize base respective estimate useful life point time period asset consider indefinite live amortize test impairment annual basis annual test aware event change indicate likely fair value iprd project respective carrying amount fair value indefinitelive intangible asset dependent assumption expect timing probability achieve specify milestone change project revenue change discount rate significant judgment employ determine assumption change assumption significant impact result operation give period estimate fair value iprd relate momelotinib simtuzumab write zero termination clinical development program result record impairment charge million research development expense consolidate statement income include item annual report intangible asset finite useful life amortize estimate useful life primarily straightline basis intangible asset finite useful life review impairment fact circumstance suggest carry value asset recoverable tax provision estimate income tax provision include defer tax asset liability base significant management judgment evaluate realization portion defer tax asset quarterly basis record valuation allowance reduce defer tax asset amount likely realize consider future taxable income ongoing tax planning strategy historical financial performance assess need valuation allowance expect realize defer tax asset previously record valuation allowance reduce valuation allowance period determination valuation allowance million december million december increase valuation allowance december december primarily write iprd value momelotinib subject income taxis unite states foreign jurisdiction include ireland economic political condition country actively consider change exist tax law predict form time potential legislative change material adverse impact result operation addition significant judgment require determine worldwide provision income taxis record liability relate uncertain tax position accordance guidance clarifie accounting uncertainty income taxis recognize enterprise financial statement prescribe minimum recognition threshold measurement attribute financial statement recognition measurement tax position take expect take tax return adverse resolution uncertain tax position period material impact result operation period december total federal state foreign unrecognized tax benefit billion billion respectively total unrecognized tax benefit billion billion december respectively recognize reduce effective tax rate period recognition december believe unrecognized tax benefit significantly change month high degree uncertainly time clarification irs tax authority uncertain tax position unable reasonably estimate period cash settlement respective tax authority file federal state foreign income tax return unite states jurisdiction abroad federal income tax purpose statute limitation open onwards certain acquire entity statute limitation open year inception utilization net operating loss credit carry prior year california income tax purpose statute limitation open onwards income tax return subject audit federal state foreign tax authority currently examination irs tax year state foreign jurisdiction differ interpretation tax law regulation result significant dispute arise tax authority involve issue time deduction allocation income tax jurisdiction periodically evaluate exposure associate tax filing position balance sheet arrangement balance sheet arrangement define item aii regulation sk contractual obligation contractual obligation consist debt obligation operating lease capital commitment purchase obligation active pharmaceutical ingredient inventoryrelate item clinical trial contract follow table summarize significant enforceable legally bind obligation future commitment obligation relate contract likely continue regardless fact certain obligation cancelable december million payment period contractual obligation total year year year year debt operating lease obligation capital commitment purchase obligation clinical trial total note debt primarily consist senior unsecured note include principal interest payment interest payment incur calculate base term relate note note debt credit facility note consolidated financial statement include item annual report additional information amount include firm capital project commitment primarily relate construction new building amount include firm purchase commitment primarily relate active pharmaceutical ingredient certain inventoryrelate item amount include minimum purchase requirement addition commit potential future milestone payment party license collaboration development arrangement payment agreement generally payable achievement certain developmental regulatory andor commercial milestone achievement milestone probable reasonably estimable contingency record consolidated balance sheet include table december clinical study clinical trial phase significant clinical trial expenditure contract research organization cro material contract cro cancelable historically cancel contract amount reflect commitment base exist contract reflect future modification termination exist contract anticipate potential new contract december consolidated balance sheet reflect liability unrecognize tax position interest penalty total billion high degree uncertainty time future cash settlement event extinguish liability unable estimate period cash settlement exclude liability relate unrecognized tax position table recent accounting pronouncement information require item include note organization summary significant accounting policy note consolidated financial statement include item annual report item quantitative qualitative disclosure market risk expose market risk result change foreign currency exchange rate interest rate credit risk reduce certain risk enter type foreign currency interest rate derivative hedging transaction follow investment guideline monitor outstanding receivables risk management program foreign currency exchange risk operation include manufacture sale activity united states canada ireland sale activity country outside united states include europe asia pacific result financial result significantly affect factor change foreign currency exchange rate weak economic condition foreign market distribute product operating result expose change foreign currency exchange rate dollar foreign currency significant euro yen dollar strengthen currency relative value sale respective foreign currency decrease conversely dollar weaken currency relative amount sale increase overall net receiver foreign currency benefit weak dollar adversely affect strong dollar relative foreign currency transact significant amount business approximately product sale denominate foreign currency partially mitigate impact change currency exchange rate net cash flow foreign currency denominate sale enter foreign currency exchange forward option contract hedge certain monetary asset liability denominate foreign currency reduce eliminate exposure currency fluctuation date transaction record date cash collect pay general market risk contract offset correspond gain loss transaction hedge december open foreign currency forward contract notional amount billion billion respectively hypothetical adverse movement foreign currency exchange rate compare dollar relative exchange rate december resulted reduction fair value contract approximately million date realize negatively affect earning remain life contract hypothetical movement foreign currency exchange rate compare dollar relative exchange rate december resulted reduction fair value contract approximately million date realize negatively affect earning remain life contract analysis consider impact hypothetical change foreign currency exchange rate anticipated transaction foreign currency sensitive instrument design offset interest rate risk portfolio availableforsale marketable security fix variable rate liability create exposure interest rate risk respect investment portfolio adhere investment policy require limit amount invest security base credit rating maturity industry group investment type issuer security issue government goal investment policy order priority follow safety preservation principal diversification risk liquidity investment sufficient meet cash flow requirement competitive aftertax rate return follow table summarize expect maturity average interest rate interestgenerate asset interestbeare liability december millions percentage expect maturity total fair total value asset availableforsale debt security average interest rate liabilitie debt average interest rate note december debt consist primarily fix rate senior unsecured note report amortize cost consolidated balance sheet instrument bear interest fix rate change interest rate affect interest expense cash flow fair value instrument fluctuate interest rate change addition senior unsecured note billion fiveyear revolve credit facility interest charge loan revolve credit facility base float rate fluctuate interest rate change amount outstanding revolve credit facility december note debt credit facility note consolidated financial statement include item annual report additional information credit risk subject credit risk portfolio cash equivalent marketable security investment policy limit amount invest security credit rating maturity industry group investment type issuer security issue government expose significant concentration credit risk financial instrument goal investment policy order priority follow safety preservation principal diversification risk liquidity investment sufficient meet cash flow requirement competitive aftertax rate return subject credit risk account receivable relate product sale majority trade account receivable arise product sale united states europe december account receivable net southern europe specifically greece italy portugal spain total approximately million million great day past include million great day past december account receivable net southern europe specifically greece italy portugal spain total approximately million million great day past include million great day past date experience significant loss respect collection account receivable item financial statement supplementary datum gilead sciences inc index consolidated financial statement supplementary data year end december content report independent register public accounting firm audit consolidated financial statement consolidate balance sheet consolidate statement income consolidate statement comprehensive income consolidate statement stockholder equity consolidate statement cash flow note consolidated financial statement select quarterly financial information unaudite schedule ii valuation qualifying account report independent register public accounting firm board director stockholder gilead sciences inc audit accompany consolidated balance sheet gilead sciences inc december relate consolidated statement income comprehensive income stockholder equity cash flow year period end december audits include financial statement schedule list index item financial statement schedule responsibility company management responsibility express opinion financial statement schedule base audit conduct audits accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance financial statement free material misstatement audit include examine test basis evidence support amount disclosure financial statement audit include assess accounting principle significant estimate management evaluate overall financial statement presentation believe audits provide reasonable basis opinion opinion financial statement refer present fairly material respect consolidate financial position gilead sciences inc december consolidate result operation cash flow year period end december conformity generally accept accounting principle opinion relate financial statement schedule consider relation basic financial statement take present fairly material respect information set forth audit accordance standard public company accounting oversight board united states gilead sciences inc internal control financial reporting december base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission framework report date february express unqualified opinion thereon ernst young llp redwood city california february gilead sciences inc consolidated balance sheet million share amount december asset current asset cash cash equivalent shortterm marketable security account receivable net allowance december december inventory defer tax asset prepay current asset total current asset property plant equipment net longterm portion prepay royalty longterm defer tax asset longterm marketable security intangible asset net goodwill longterm asset total asset liability stockholder equity current liability account payable accrue government rebate accrue liability defer revenue current portion longterm debt obligation net total current liability longterm debt net longterm income taxis payable longterm obligation commitment contingency note equity component currently redeemable convertible note stockholder equity prefer stock par value share share authorize outstanding common stock par value share share authorize december december share issue outstanding december december additional paidin capital accumulate comprehensive income retain earning total gilead stockholder equity noncontrolle interest total stockholder equity total liability stockholder equity accompany note gilead sciences inc consolidated statement income million share amount year end december revenue product sale royalty contract revenue total revenue cost expense cost good sell research development expense sell general administrative expense total cost expense income operation interest expense income expense net income provision income taxis provision income taxis net income net loss attributable noncontrolle interest net income attributable gilead net income share attributable gilead common stockholder basic share share calculation basic net income share attributable gilead common stockholder dilute share share calculation dilute cash dividend declare share accompany note gilead sciences inc consolidated statement comprehensive income million year end december net income comprehensive income loss net foreign currency translation gain loss net tax availableforsale security net unrealize gain loss net tax impact respectively reclassification net income net tax impact respectively net change cash flow hedge net unrealized gain net tax impact respectively reclassification net income net tax impact respectively net change comprehensive income loss comprehensive income comprehensive loss attributable noncontrolle interest comprehensive income attributable gilead accompany note gilead sciences inc consolidated statement stockholders equity millions gilead stockholder equity common stock accumulate additional total paidin comprehensive retain noncontrolle stockholder share capital income loss earning interest equity balance december change noncontrolle interest net income loss comprehensive income net tax issuance employee stock purchase plan issuance equity incentive plan tax benefit employee stock plan stockbase compensation repurchase common stock warrant settlement convertible note settlement convertible note hedge settlement purchase convertible note hedge reclassification equity component currently redeemable convertible note balance december change noncontrolle interest net income loss comprehensive loss net tax issuance employee stock purchase plan issuance equity incentive plans tax benefit employee stock plan stockbase compensation repurchase common stock warrant settlement convertible note settlement convertible note hedge settlement dividend declare reclassification equity component currently redeemable convertible note balance december change noncontrolle interest net income loss comprehensive income net tax issuance employee stock purchase plan issuance equity incentive plans tax benefit employee stock plan stockbase compensation repurchase common stock warrant settlement convertible note settlement convertible note hedge settlement dividend declare reclassification conversion spread convertible note reclassification convertible note hedge reclassification equity component currently redeemable convertible note balance december accompany note gilead sciences inc consolidated statement cash flow millions year end december operating activity net income adjustment reconcile net income net cash provide operating activity depreciation expense amortization expense stockbase compensation expense excess tax benefit stockbase compensation tax benefit exercise vest stockbased award defer income taxis inprocess research development impairment change operate asset liability account receivable net inventory prepaid expense account payable income taxis payable accrue liability defer revenue net cash provide operating activity invest activity purchase marketable security proceed sale marketable security proceed maturitie marketable security investment capital expenditure net cash investing activity financing activity proceed debt finance net issuance cost proceed convertible note hedge purchase convertible note hedge proceed issuance common stock repurchase common stock repayment debt obligation payment settle warrant excess tax benefit stockbase compensation payment contingent consideration payment dividend contribution distribution noncontrolle interest net cash financing activity effect exchange rate change cash cash equivalent net change cash cash equivalent cash cash equivalent begin period cash cash equivalent end period supplemental disclosure cash flow information interest pay net amount capitalize income taxis pay accompany note gilead sciences inc note consolidated financial statement organization summary significant accounting policy overview gilead sciences inc gilead incorporate delaware june researchbase biopharmaceutical company discover develop commercialize innovative medicine area unmet medical need new discovery investigational drug candidate strive transform simplify care people lifethreatene illness world operation country worldwide headquarters foster city california gileads primary area focus include human immunodeficiency virus hiv liver disease chronic hepatitis c virus hcv infection chronic hepatitis b virus hbv infection hematologyoncology cardiovascular inflammationrespiratory disease seek add exist portfolio product internal discovery clinical development program product acquisition inlicense strategy portfolio market product include ambisome atripla cayston compleraeviplera descovy emtriva epclusa genvoya harvoni hepsera letairis odefsey ranexa sovaldi stribild truvada tybost vemlidy viread vitekta zydelig international commercial sale operation marketing subsidiary country sell distribute certain product corporate partner royaltypaye collaborative agreement basis presentation accompany consolidated financial statement include account gilead whollyowne subsidiary certain variable interest entity primary beneficiary intercompany transaction eliminate consolidated entity expose economic record net income loss attributable noncontrolle interest consolidate statement income equal percentage economic ownership interest retain entity respective noncontrolle party assess primary beneficiary variable interest entity vie inception arrangement reporting date assessment base power direct activity vie significantly impact vie economic performance obligation absorb loss right receive benefit vie potentially significant vie december material vie joint venture bristolmyer squibb bms describe note collaborative arrangement significant accounting policy estimate judgment preparation consolidated financial statement require estimate judgment affect report amount asset liability revenue expense related disclosure ongoing basis evaluate significant accounting policy estimate base estimate historical experience market specific relevant assumption believe reasonable circumstance result form basis make judgment carry value asset liability readily apparent source actual result differ significantly estimate revenue recognition product sale recognize revenue product sale persuasive evidence arrangement exist delivery occur price fix determinable collectability reasonably assure recognition revenue product sale provision government rebate medicaid reimbursement customer incentive cash discount prompt payment distributor fee expect return expire product appropriate item deduct gross product sale rebate chargeback estimate reduction revenue amount pay payer healthcare providers united states include medicaid rebate aid drug assistance program veterans administration public health service discount rebate foreign government rebate rebate chargeback base contractual arrangement statutory requirement vary product payer individual payer plan estimate base product sell historical utilization rate available pertinent thirdparty industry information estimate patient population know market event trend product sale channel inventory datum obtain major wholesaler accordance inventory management agreement consideration available new information change program regulation guideline impact actual rebate andor expectation future utilization rate program government chargeback payable direct customer classify reduction account receivable consolidated balance sheet government rebate invoice directly record accrue government rebate consolidated balance sheet cash discount estimate cash discount base contractual term historical utilization rate expectation future utilization rate distributor fee inventory management agreement significant wholesaler pay wholesaler fee primarily compliance certain contractually determine covenant maintenance agree inventory level distributor fee base contractually determine fix percentage sale product return provide customer general right product return typically permit return product damage defective receive customer case product sell united states certain country outside united states product expire accept return product expire month expire year expiration date estimate expect return expire product base primarily ongoing analysis historical return pattern historical industry information report return rate similar product contractual agreement intend limit inventory maintain wholesaler royalty contract revenue royalty revenue sale product generally recognize receive generally quarter follow quarter correspond sale occur month follow month correspond sale occur revenue nonrefundable upfront license fee milestone payment development collaboration obligation supply product recognize performance occur obligation complete accordance specific term obligation arrangement revenue recognize obligation fulfil ratably development manufacturing period revenue associate substantive atrisk milestone recognize base achievement milestone set forth respective agreement advance payment receive excess amount earn classified defer revenue consolidated balance sheet research development expense research development rd expense consist primarily personnel cost include salary benefit stockbase compensation clinical study perform contract research organization cro material supply license fee upfront milestone payment collaboration arrangement overhead allocation consist support facilityrelate cost charge rd cost include clinical study cost expense incur clinical study cost significant component rd expense clinical study perform thirdparty cro monitor level performance significant contract include extent patient enrollment activity communication cro accrue cost clinical study perform cro service period specify contract adjust estimate require base ongoing review level effort cost actually incur cro material cro contract terminable write notice generally liable actual service complete cro certain noncancelable expense incur point termination advertising expense expense cost advertising include promotional expense incur advertising expense million million million cash cash equivalent consider highly liquid investment insignificant interest rate risk original maturity month purchase date cash equivalent eligible instrument investment policy include cash equivalent primarily include commercial paper money market fund overnight repurchase agreement repos major bank authorize dealer bank obligation marketable nonmarketable security determine appropriate classification marketable security consist primarily debt security time purchase reevaluate designation balance sheet date marketable security consider availableforsale carry estimate fair value report cash equivalent shortterm marketable security longterm marketable security unrealize gain loss availableforsale security exclude net income report accumulate comprehensive income loss aoci separate component stockholder equity income expense net include interest dividend amortization purchase premium discount realize gain loss sale security otherthantemporary decline fair value security cost security sell base specific identification method regularly review investment otherthan temporary decline fair value review include consideration cause impairment include creditworthiness security issuer number security unrealize loss position severity duration unrealize loss intent sell security likely require sell security recovery amortize cost basis determine decline fair value investment accounting basis decline otherthantemporary reduce carry value security hold record loss decline result enter collaboration time time hold investment public nonpublic company record investment public company availableforsale security market value record investment nonpublic company cost amount otherthantemporary impairment asset consolidate balance sheet unrealize gain loss availableforsale security exclude net income report aoci regularly review security indicator impairment investment nonpublic company material period present concentration risk subject credit risk portfolio cash equivalent marketable security investment policy limit amount invest security credit rating maturity industry group investment type issuer security issue government expose significant concentration credit risk financial instrument goal investment policy order priority follow safety preservation principal diversification risk liquidity investment sufficient meet cash flow requirement competitive aftertax rate return subject credit risk account receivable relate product sale majority trade account receivable arise product sale united states europe japan december account receivable net southern europe specifically greece italy portugal spain total approximately million million great day past include million great day past date experience significant loss respect collection account receivable believe allowance doubtful account adequate december certain raw material component utilize operation obtain single supplier certain raw material utilize operation facility supplier key component raw material name new drug application nda file food drug administration fda product significant delay occur qualification new supplier require delivery material supplier interrupt reason unable ship commercial product supply product candidate clinical trial account receivable trade account receivable record net allowance wholesaler chargeback relate government program cash discount prompt payment doubtful account estimate wholesaler chargeback government program cash discount base contractual term historical trend expectation utilization rate program estimate allowance doubtful account determine base exist contractual payment term historical payment pattern customer individual customer circumstance analysis day sale outstanding geographic region review local economic environment potential impact government funding reimbursement practice historically amount uncollectible account receivable write insignificant inventory inventory record low cost market cost determine firstin firstout basis periodically review composition inventory order identify obsolete slowmoving unsaleable item unsaleable item observe alternate use inventory record writedown net realizable value period impairment recognize future commercialization consider probable future economic benefit expect realize base management judgment capitalize prelaunch inventory cost prior regulatory approval number factor take consideration include current status regulatory approval process potential impediment approval process safety efficacy anticipate rd initiative impact indication compound viability commercialization marketplace trend december prelaunch inventory consolidate balance sheet significant property plant equipment property plant equipment state cost accumulate depreciation amortization depreciation amortization recognize straight line method repair maintenance cost expense incur estimate useful life year generally follow description estimate useful life building improvement laboratory manufacturing equipment office computer equipment leasehold improvement short useful life lease term office computer equipment include capitalize software unamortize capitalize software cost consolidate balance sheet million december million december capitalize interest construction inprogress include property plant equipment interest capitalize significant goodwill intangible asset goodwill represent excess consideration transfer estimate fair value asset acquire liability assume business combination intangible asset indefinite useful life relate purchase inprocess research development iprd project measure respective fair value acquisition date amortize goodwill intangible asset indefinite useful live intangible asset relate iprd project consider indefinitelive completion abandonment associate rd effort development complete generally occur regulatory approval market product obtain associate asset deem finitelive amortize base respective estimate useful life point time test goodwill indefinitelive intangible asset impairment annual basis annual test aware event change indicate fair value asset carry amount intangible asset finite useful life amortize estimate useful life primarily straightline basis review impairment fact circumstance suggest carry value asset recoverable impairment longlive asset longlive asset include property plant equipment finitelive intangible asset review impairment fact circumstance internally externally suggest carry value asset asset group recoverable indication impairment test recoverability compare estimate undiscounted future cash flow expect result use asset asset group eventual disposition carry asset asset group excess carrying value asset asset group estimate fair value recognize impairment loss foreign currency translation transaction gain loss hedge contract nonus entity operation record functional currency entity result operation nonus dollar functional currency entity translate dollar average currency rate asset liability translate currency rate period end foreign currency translation adjustment record component aoci stockholder equity foreign currency transaction gain loss record income expense net consolidated statement income net foreign currency transaction gain loss immaterial year end december hedge portion foreign currency exposure related outstanding monetary asset liability forecast product sale foreign currency exchange forward option contract general market risk relate contract offset correspond gain loss hedge transaction credit risk associate contract drive change interest currency exchange rate result vary time work major bank closely monitor current market condition seek limit risk counterpartie contract unable perform seek limit risk loss enter contract permit net settlement maturity overall risk loss event counterparty default limit unrecognized gain outstanding contract ie contract positive fair value date default enter derivative contract trading purpose hedge net investment foreign subsidiary fair value financial instrument apply fair value account financial asset liability nonfinancial asset liability recognize disclose fair value financial statement recur basis define fair value price receive sell asset pay transfer liability orderly transaction market participant measurement date determine fair value measurement asset liability require record fair value consider principal advantageous market transact marketbase risk measurement assumption market participant use price asset liability risk inherent valuation technique transfer restriction credit risk derivative financial instrument recognize derivative instrument asset liabilitie fair value consolidate balance sheet change fair value derivative record period current earning aoci depend derivative designate hedge transaction type hedge transaction classify cash flow instrument category cash flow hedge item hold issue derivative instrument trade speculative purpose assess inception ongoing basis derivative hedging transaction highly effective offset change cash flow fair value hedge item assess hedge ineffectiveness quarterly basis record gain loss relate ineffective portion current earning extent significant determine forecast transaction probable occur discontinue hedge accounting affect portion hedge instrument relate unrealized gain loss contract recognize income expense net consolidated statement income income taxis income tax provision compute liability method defer tax asset liability determine base difference financial statement tax basis asset liability enact tax rate effect year difference expect reverse significant estimate require determine provision income taxis estimate base interpretation exist tax law regulation record liability relate uncertain tax position accordance guidance clarifie accounting uncertainty income taxis recognize enterprise financial statement prescribe minimum recognition threshold measurement attribute financial statement recognition measurement tax position take expect take tax return adverse resolution uncertain tax position period material impact result operation period brand prescription drug bpd fee pharmaceutical manufacturer brand drug product require pay portion bpd fee estimate base select government sale calendar year percentage total industry government sale truedup receipt invoice internal revenue service irs irs issue final regulation relate bpd fee accelerate expense recognition criterion fee obligation year fee pay year relate sale market share allocate fee determine bpd fee expense million million million record sell general administrative sga expense consolidate statement income bpd fee accrual total million december million december consolidated balance sheet recent accounting pronouncement financial accounting standard board fasb issue accounting standard update asu revenue contract customer standard core principle report entity recognize revenue transfer promise good service customer reflect consideration entity expect entitled exchange good service standard effective begin quarter early adoption permit entity option retrospective modify retrospective approach adopt new guidance fasb issue supplemental adoption guidance clarification asu march april december asu revenue contract customer principal vs agent consideration asu revenue contract customer identify performance obligation license asu revenue contract customer narrowscope improvement practical expedient asu technical correction improvement topic revenue contract customer respectively expect adopt accounting standard update modify retrospective approach cumulative effect adopt accounting standard update record retain earning january complete initial assessment effect adoption base assessment expect change revenue recognition policy relate royalty revenue certain revenue currently recognize cash basis sell method adoption accounting standard update revenue recognize period sale occur subject constraint variable consideration currently expect accounting standard update material impact consolidate financial statement november fasb issue accounting standard update asu balance sheet classification defer taxis asu require defer tax liability asset classify noncurrent balance sheet previous guidance require defer tax liability asset separate current noncurrent amount balance sheet plan adopt guidance quarter retrospective basis reclassify current defer tax amount consolidate balance sheet noncurrent january fasb issue accounting standard update asu recognition measurement financial asset financial liability asu change account equity investment financial liability fair value option presentation disclosure requirement financial instrument addition clarify guidance relate valuation allowance assessment recognize defer tax asset result unrealized loss availableforsale debt security guidance effective begin quarter adopt modify retrospective approach certain exception early adoption permit certain provision evaluate impact adoption standard consolidated financial statement february fasb issue accounting standard update asu lease asu amend number aspect lease accounting include require lessee recognize lease term great year rightofuse asset correspond liability measure present value lease payment guidance effective begin quarter require adopt modify retrospective approach early adoption permit evaluate impact adoption standard consolidated financial statement anticipate recognition additional asset correspond liability relate lease consolidated balance sheet march fasb issue accounting standard update asu improvement employee sharebase payment account new guidance require excess tax benefit deficiency arise vest exercise sharebase payment recognize income statement current guidance tax effect record additional paidincapital guidance amend presentation certain share base payment item statement cash flow adopt guidance quarter adopt aspect new guidance affect cash flow presentation retrospectively elect continue estimate potential forfeiture anticipate adoption guidance result increase share calculation dilute earning share depend primarily time employee exercise stock option stock price time anticipate cumulativeeffect adjustment record retain earning adoption relate amendment require modified retrospective transition currently expect adopt guidance material impact consolidate financial statement june fasb issue accounting standard update asu measurement credit loss financial instrument asu require measurement recognition expect credit loss financial asset guidance effective begin quarter adopt modify retrospective approach certain exception early adoption permit begin quarter evaluate impact adoption standard consolidated financial statement january fasb issue accounting standard update asu clarify definition business new guidance clarifie definition business evaluate transaction account acquisition disposal asset business guidance effective begin quarter early adoption permit evaluate impact adoption standard consolidated financial statement fair value measurement determine fair value financial nonfinancial asset liability fair value hierarchy establish level input measure fair value follow level input include quote price active market identical asset liability level input include observable input level input quote price similar asset liability quote price identical similar asset liability market active input observable corroborate observable market datum substantially term asset liability marketable security review trading activity pricing measurement date sufficient quote price identical security available use market pricing observable market input similar security obtain thirdparty datum provider input represent quote price similar asset active market derive observable market datum level input include unobservable input support little market activity significant fair value underlie asset liability level asset liability include fair value measurement determine pricing model discount cash flow methodology similar valuation technique significant management judgment estimation financial instrument consist primarily cash cash equivalent marketable security account receivable foreign currency exchange contract equity security account payable shortterm longterm debt cash cash equivalent marketable security foreign currency exchange contract equity security report respective fair value consolidate balance sheet shortterm longterm debt report amortize cost consolidate balance sheet remain financial instrument report consolidated balance sheet amount approximate current fair value transfer level level level period present follow table summarize type asset liability measure fair value recur basis level fair value hierarchy million december december level level level total level level level total asset corporate debt security treasury security money market fund residential mortgage assetbacke security government agency security certificate deposit nonus government security foreign currency derivative contract defer compensation plan municipal debt security equity security total liability defer compensation plan foreign currency derivative contract contingent consideration total level input estimate fair value level instrument take consideration valuation obtain thirdparty pricing service pricing service utilize industry standard valuation model include income marketbase approach significant input observable directly indirectly estimate fair value input include report trade brokerdealer quote similar security issuer credit spread benchmark security prepaymentdefault projection base historical datum observable input substantially foreign currency derivative contract maturity month time horizon counterpartie minimum credit rating equivalent standard poor rating service moodys investors service inc fitch inc estimate fair value contract take consideration valuation obtain thirdparty valuation service utilize incomebase industry standard valuation model significant input observable directly indirectly input include foreign currency exchange rate london interbank offer rate libor swap rate input applicable commonly quote interval total estimate fair value shortterm longterm debt determine level input base quote market value approximately billion december billion december carry value billion december billion december level input december asset liability measure level input recur basis contingent consideration liability immaterial nonrecurre basis measure certain asset include intangible asset fair value carry value asset exceed fair value estimate fair value iprd relate momelotinib simtuzumab write zero termination clinical development program result record impairment charge million note intangible asset additional information policy recognize transfer level classification actual date event change circumstance cause transfer availableforsale security estimate fair value availableforsale security generally base price obtain commercial pricing service follow table summary availableforsale security millions december december gross gross gross gross amortize unrealize unrealized estimate amortize unrealize unrealized estimate cost gain loss fair value cost gain loss fair value corporate debt security treasury security money market fund residential mortgage asset back security government agency security certificate deposit nonus government security municipal debt security equity security total follow table summarize classification availableforsale security consolidate balance sheet million december december cash cash equivalent shortterm marketable security longterm marketable security longterm asset total cash cash equivalent table exclude cash billion december billion december follow table summarize portfolio availableforsale debt security contractual maturity million december amortize cost fair value year great year year great year year great year total follow table summarize availableforsale debt security continuous unrealized loss position deem otherthan temporarily impair million month month great total gross gross gross unrealize estimate unrealized estimate unrealized estimate loss fair value loss fair value loss fair value december corporate debt security treasury security residential mortgage assetbacke security government agency security nonus government security certificate deposit municipal debt security total december corporate debt security treasury security residential mortgage assetbacke security government agency security nonus government security municipal debt security total hold total position december position december relate debt security unrealize loss position base review availableforsale security believe otherthantemporary impairment security december intend sell security believe require sell security recovery amortize cost basis gross realize gain gross realize loss immaterial year end december derivative financial instrument foreign currency exposure operation foreign country expose market risk associate foreign currency exchange rate fluctuation dollar foreign currency significant euro yen order manage risk hedge portion foreign currency exposure related outstanding monetary asset liability forecast product sale foreign currency exchange forward option contract general market risk relate contract offset correspond gain loss hedge transaction credit risk associate contract drive change interest currency exchange rate result vary time work major bank closely monitor current market condition seek limit risk counterpartie contract unable perform seek limit risk loss enter contract permit net settlement maturity overall risk loss event counterparty default limit unrecognized gain outstanding contract ie contract positive fair value date default enter derivative contract trading purpose hedge exposure foreign currency exchange rate fluctuation certain monetary asset liability entity denominate non functional currency derivative instrument use hedge exposure designate hedge result change fair value record income expense net consolidated statement income hedge exposure foreign currency exchange rate fluctuation forecast product sale denominate nonfunctional currency derivative instrument use hedge exposure designate cash flow hedge maturity date month execute hedge contract quarterly assess prospective hedge effectiveness regression analysis calculate change cash flow result hedge instrument quarterly basis assess retrospective hedge effectiveness dollar offset approach exclude time value effectiveness testing recognize change time value hedge income expense net effective component hedge record unrealized gain loss hedge instrument aoci stockholder equity gain loss reclassify product sale hedge transaction affect earning majority gain loss relate hedged forecast transaction report aoci december expect reclassify product sale month cash flow effect derivative contract year end december include net cash provide operating activity consolidate statement cash flow notional amount foreign currency exchange contract outstanding billion december billion december derivative contract allow right offset asset liability present amount gross basis international swap dealers association inc master agreement respective counterpartie foreign currency exchange contract subject applicable requirement allow net settle transaction currency single net payable party follow table summarize classification fair value derivative instrument consolidate balance sheet million december asset derivative liability derivative fair classification fair value classification value derivative designate hedge foreign currency exchange contract current asset accrue liability foreign currency exchange contract longterm asset longterm obligation total derivative designate hedge derivative designate hedge foreign currency exchange contract current asset accrue liability foreign currency exchange contract longterm asset longterm obligation total derivative designate hedge total derivative december asset derivative liability derivative fair classification fair value classification value derivative designate hedge foreign currency exchange contract current asset accrue liability foreign currency exchange contract longterm asset longterm obligation total derivative designate hedge derivative designate hedge foreign currency exchange contract current asset accrue liability total derivative designate hedge total derivative follow table summarize effect foreign currency exchange contract consolidate financial statement millions year end december derivative designate hedge gain recognize aoci effective portion gain reclassify aoci product sale effective portion gain loss recognize income expense net ineffective portion amount exclude effectiveness testing derivative designate hedge gain recognize income expense net time time discontinue cash flow hedge result record relate amount income expense net consolidated statement income material amount record income expense net year end december result discontinuance cash flow hedge december hold type financial instrument derivative contract relate foreign currency exchange contract follow table summarize potential effect offset derivative type financial instrument consolidated balance sheet million december offset derivative assetsliabilitie gross amount offset consolidated balance sheet gross amount offset amount assetsliabilitie gross amount consolidated balance present consolidated derivative financial cash collateral net description recognize assetsliabilitie sheet balance sheet instrument receivedpledge legal offset derivative asset derivative liability december offset derivative assetsliabilitie gross amount offset consolidated balance sheet gross amount offset amount assetsliabilitie gross amount consolidated balance present consolidated derivative financial cash collateral net description recognize assetsliabilitie sheet balance sheet instrument receivedpledge legal offset derivative asset derivative liability convertible senior note convertible note hedge march exercise option elect cash settlement conversion value excess principal conversion spread remain convertible senior note convertible note relate convertible note hedge cash settlement election conversion spread convertible note convertible note hedge meet applicable criterion equity classification record stockholder equity consolidated balance sheet cash settlement election reclassify million fair value conversion spread stockholders equity current portion longterm debt obligation net reclassify million fair value convertible note hedge stockholder equity prepay current asset consolidate balance sheet maturity convertible note settle conversion spread convertible note hedge cash million respectively record loss million conversion spread gain million convertible note hedge consolidate statement income inventory inventory summarize follow million december raw material work process finish good total report inventory longterm asset total amount report longterm asset primarily consist raw material december december joint venture form gilead sciences llc bms note collaborative arrangement include consolidated financial statement hold efavirenz active pharmaceutical ingredient inventory efavirenz inventory purchase bms bmss estimate net selling price efavirenz total billion december billion december property plant equipment property plant equipment summarize follow million december land building improvement include leasehold improvement laboratory manufacturing equipment office computer equipment construction progress subtotal accumulate depreciation amortization total intangible asset follow table summarize carry intangible asset net million december finitelive intangible asset indefinitelive intangible asset total finitelive intangible asset follow table summarize finitelive intangible asset millions december december gross carry accumulate net carry gross carry accumulate net carrying amortization amortization intangible asset sofosbuvir intangible asset ranexa total amortization expense relate finitelived intangible asset include primarily cost good sell consolidated statement income total million million million december estimate future amortization expense associate finitelive intangible asset succeed fiscal year follow millions fiscal year total indefinitelive intangible asset follow table summarize indefinitelive intangible asset million december indefinitelive intangible asset momelotinib indefinitelive intangible asset simtuzumab total estimate fair value iprd relate momelotinib simtuzumab write zero termination clinical development program result record impairment charge million research development expense consolidate statement income financial information prepay current asset component prepay current asset summarize follow million december prepay taxis prepaid expense current asset total accrue liability component accrue liability summarize follow million december bpd fee compensation employee benefit accrue interest accrue expense total acquisition acquire nimbus apollo inc privately hold company acetylcoa carboxylase inhibitor program evaluate potential treatment nonalcoholic steatohepatitis hepatocellular carcinoma disease consideration include payment million contingent development regulatory milestonebase payment million transaction meet requirement account business combination asc business combination account asset acquisition result payment million record research development expense consolidate statement income base achievement certain clinical development milestone record million expense research development expense consolidate statement income collaborative arrangement enter collaborative arrangement party development commercialization certain product party active participant operating activity collaboration expose significant risk reward depend commercial success activity follow significant collaborative arrangement bristolmyers squibb company north america enter collaboration arrangement bms develop commercialize singletablet regiman contain truvada bmss sustiva efavirenz united states combination approve use united states sell brand atripla bms structure collaboration joint venture operate limited liability company name bristolmyers squibb gilead sciences llc consolidate bms grant royaltyfree sublicense joint venture use respective company own technology return grant license joint venture use intellectual property result collaboration bms amend joint venture collaboration agreement allow joint venture sell atripla canada economic interest joint venture hold bms include share revenue outofpocket expense base portion net selling price atripla attributable efavirenz truvada net selling price truvada change time relative net selling price efavirenz bmss respective economic interest joint venture vary annually bms share marketing sale effort start second quarter limited number activity jointly manage party long coordinate detail promotional activity united states party reduce joint promotional effort launch complera august stribild august party continue collaborate activity manufacture regulatory compliance pharmacovigilance daily operation joint venture govern joint committee form bms gilead responsible accounting financial reporting tax reporting manufacturing product distribution joint venture party provide respective bulk active pharmaceutical ingredient joint venture approximate market value agreement continue terminate mutual agreement party addition party terminate party participation collaboration day launch generic version party single agent product double agent product terminate party right continue sell atripla continue party obligate pay terminate party certain royalty threeyear period follow effective date termination loss exclusivity united states sustiva expect december december joint venture hold efavirenz active pharmaceutical ingredient purchase bms bmss estimate net selling price efavirenz market amount primarily include inventory consolidate balance sheet select financial information joint venture follow million december total asset cash cash equivalent account receivable net inventory total liability account payable accrue liability asset liability amount reflect impact intercompany elimination include consolidated balance sheet consolidate joint venture legal structure joint venture limit recourse creditor general credit asset similarly asset hold joint venture settle obligation joint venture europe gilead sciences ireland uc whollyowne subsidiary bms enter collaboration agreement set forth term condition bms commercialize distribute atripla european union iceland liechtenstein norway switzerland collectively european territory party form limited liability company consolidate manufacture atripla distribution european territory efavirenz purchase bms bmss estimate net selling price efavirenz european territory responsible manufacturing product distribution inventory management warehouse local subsidiary primary responsibility order fulfillment collection receivables customer relation handle sale return territory bms promote atripla general party share revenue outofpocket expense proportion net selling price component atripla truvada efavirenz start limited number activity jointly manage party long coordinate detail promotional activity european territory responsible accounting financial reporting tax reporting collaboration december efavirenz purchase bms bmss estimate net selling price efavirenz european territory include inventory consolidate balance sheet party form limited liability company hold marketing authorization atripla european territory primary responsibility regulatory activity major market country party agree independently continue use commercially reasonable effort promote atripla agreement terminate expiration lasttoexpire patent afford market exclusivity atripla component european territory addition december party terminate agreement reason termination effective calendar quarter notice termination nonterminate party right continue sell atripla continue party obligate pay terminate party certain royalty threeyear period follow effective date termination event continue party decide sell atripla effective date termination date atripla withdraw country date party assume distribution atripla whichever early japan tobacco inc japan tobacco inc japan tobacco grant exclusive right develop commercialize elvitegravir novel hiv integrase inhibitor country world exclude japan japan tobacco retain right agreement responsible seek regulatory approval territory require use diligent effort commercialize elvitegravir treatment hiv infection bear cost expense associate commercialization effort receive approval stribild elvitegravircontaine product fda august european commission receive approval genvoya elvitegravircontaine product fda european commission november agreement obligation pay royalty japan tobacco terminate productbyproduct basis patent provide exclusivity product expire later tenth anniversary commercial launch product terminate agreement reason case license grant japan tobacco terminate party terminate agreement response material breach party janssen enter license collaboration agreement janssen sciences ireland uc janssen tibotec pharmaceutical develop commercialize fixeddose combination truvada janssen nonnucleoside reverse transcriptase inhibitor rilpivirine combination approve united states european union sell brand complera united states eviplera european union original agreement janssen grant exclusive license compleraeviplera worldwide exclude certain middle income develop world country japan amend agreement include distribution compleraeviplera rest world amend agreement expand collaboration include product contain janssen rilpivirine emtricitabine tenofovir alafenamide odefsey amend agreement janssen grant exclusive license compleraeviplera odefsey worldwide retain right distribute combination product country include mexico russia japan party restrict combine drug drug product similar component compleraeviplera odefsey responsible manufacturing compleraeviplera odefsey lead role registration distribution commercialization product country janssen distribute janssen exercise right codetail combination product country gilead sell party initial agreement price compleraeviplera expect sum price truvada price rilpivirine purchase separately cost rilpivirine purchase janssen compleraeviplera approximately market price rilpivirine specified percentage major market amendment effective enable sell party set price combine product party share revenue base ratio net selling price party component subject certain restriction adjustment continue retain specify percentage janssen share revenue major market party terminate collaboration agreement respect product country product withdraw market country respect product country party materially breach agreement respect product agreement party obligation share revenue expire productbyproduct countrybycountry basis janssen patent provide exclusivity product expire later tenth anniversary commercial launch product terminate agreement cause respect country sell product case janssen right sell party country product launch market few year galapagos nv closed license collaboration agreement galapagos nv galapagos clinicalstage biotechnology company base belgium development commercialization filgotinib jakselective inhibitor evaluate inflammatory disease indication closing license collaboration agreement upfront license fee payment million million equity investment galapago subscribe new share price share include issuance premium result receive million new share galapago represent outstanding share capital license fee payment million issuance premium equity investment million record research development expense consolidate statement income equity investment net issuance premium million record availableforsale security longterm asset consolidate balance sheet galapago eligible receive development regulatory milestonebase payment million salesbase milestone payment million plus tiere royalty global sale start exception certain copromotion territory profit shared equally base achievement certain clinical development milestone record million expense research development expense consolidate statement income term agreement exclusive worldwide royaltybearing sublicensable license filgotinib product contain filgotinib primarily responsible development seek regulatory approval relate filgotinib responsible galapago responsible development cost incur responsible manufacturing commercialization activity galapago option copromote filgotinib certain territory case galapago share profit equally debt credit facility financing arrangement follow table summarize carry borrowing financing arrangement million december type borrowing issue date date interest rate convertible note july senior unsecured december december senior unsecured september september senior unsecured march april senior unsecured november february senior unsecured september september senior unsecured march april senior unsecured december december senior unsecured september march senior unsecured september september senior unsecured september september senior unsecured march april senior unsecured november february senior unsecured september march senior unsecured september march senior unsecured september september senior unsecured september september senior unsecured december december senior unsecured march april senior unsecured november february senior unsecured september march senior unsecured september march floatingrate borrowing variable total debt net current portion total longterm debt net note connection adoption account standard update relate presentation debt issuance cost quarter debt balance december retrospectively adjust million include unamortized debt issuance cost prior adoption asu unamortized debt issuance cost include prepay current asset longterm asset consolidate balance sheet senior unsecured note issue billion aggregate principal senior unsecured note note register offering issue billion aggregate principal senior unsecured note note register offering note note issue general corporate purpose include repayment debt work capital payment dividend repurchase outstanding common stock pursuant authorize share repurchase program future acquisition collectively refer note note senior unsecured note issue march november notes march december note senior note senior note redeem option redemption price equal great principal note redeem ii sum determine independent investment banker present value remain schedule payment principal interest note redeem exclusive interest accrue date redemption discount redemption date semiannual basis treasury rate plus makewhole premium define indenture senior note mature feature exercisable option redeem note par month immediately precede maturity case accrue unpaid interest require redeem date redemption repay maturity million principal balance relate note event occurrence change control downgrade rate senior note investment grade standard poor rating service moodys investors service inc holder require purchase portion senior note price equal aggregate principal note repurchase plus accrue unpaid interest date repurchase require comply certain covenant senior note december violation covenant recognize million million million interest expense senior note relate contractual coupon rate amortization debt discount issuance cost convertible note july issue billion convertible note private placement pursuant rule securities act amend portion convertible note convert remainder mature repay aggregate principal balance million million respectively pay cash million million respectively relate conversion spread convertible note represent conversion value excess principal receive million million cash respectively convertible note hedge relate convertible note portion warrant relate convertible note modify settle august remainder expire pay million billion respectively settle warrant average market price common stock exceed warrant exercise price convertible note issue par bore annual interest rate initial conversion rate convertible note share principal represent initial conversion price approximately share conversion rate subject customary anti dilution adjustment include quarterly dividend distribution conversion maturity holder receive cash equal less principal note ii conversion value note measure indenture govern relevant note conversion value exceed principal deliver option cash common stock combination cash common stock conversion value excess principal concurrent issuance convertible note purchase convertible note hedge sell warrant private transaction convertible note hedge cover subject customary antidilution adjustment million share common stock strike price initially correspond initial conversion price convertible note subject adjustment similar applicable conversion price relate note include quarterly dividend distribution market value share common stock time conversion convertible note strike price applicable convertible note hedge entitle receive counterpartie transaction share common stock extent correspond election respect relate convertible note cash combination cash share common stock option excess market value common stock strike price convertible note hedge convertible note hedge terminate maturity convertible note convertible note remain outstanding conversion million share common stock underlie warrant associate convertible note warrant original exercise price share subject customary antidilution adjustment include quarterly dividend distribution enter modify agreement warrant counterpartie change time expiration million warrant modify agreement allow settle million warrant option cash share accord term modify agreement warrant expire tradingday period commence end june exercise option settle warrant cash remain million warrant expire tradingday period commence august end september exercise option settle remain warrant cash warrant settle option cash share common stock original modify agreement contract meet applicable criterion equity classification settlement payment record reduction stockholder equity consolidate balance sheet march exercise option elect cash settlement conversion spread remain convertible note relate convertible note hedge result convertible note relate convertible note hedge account derivative instrument fair value classify liability asset consolidated balance sheet note derivative financial instrument cash settlement election bifurcated conversion option convertible note debt instrument classified conversion option equity accrete result debt discount interest expense contractual term convertible note follow table summarize information equity liability component convertible note million carry value net carrying unamortized discount equity component liability component liability component december december december convertible note recognize interest expense million million million relate contractual coupon rate amortization debt discount issuance cost convertible note effective interest rate liability component convertible note credit facility terminate fiveyear billion revolve credit facility enter new billion fiveyear revolve credit facility agreement mature fiveyear revolve credit agreement new revolve credit facility work capital requirement general corporate purpose include limitation acquisition december amount outstanding credit facility fiveyear revolve credit agreement contain customary representation warranty affirmative negative covenant event default december violation covenant loan new credit facility bear interest eurodollar rate plus applicable percentage ii base rate plus applicable percentage define fiveyear revolve credit agreement terminate reduce commitment prepay loan new credit facility time premium penalty contractual maturity finance obligation december aggregate future principal maturity finance obligation year base contractual date follow millions contractual maturity commitment contingency lease arrangement lease facility equipment relate primarily administrative rd sale marketing activity longterm noncancelable operating lease united states international market lease expire date lease contain option renew lease expense operating lease approximately million million million aggregate noncancelable future minimum rental payment operating lease follow million total legal proceeding party legal action significant describe recognize accrual action extent conclude loss probable reasonably estimable accrue good estimate loss range estimate range well accrue minimum range determine loss reasonably possible loss range loss estimate disclose possible loss note possible determine outcome matter reasonably estimate maximum potential exposure range possible loss recognize accrual litigation consolidated balance sheet december believe loss probable litigation relate sofosbuvir january acquire pharmasset inc pharmasset acquisition acquire sofosbuvir nucleotide analog act inhibit replication hepatitis c virus hcv december receive fda approval sofosbuvir know commercially sovaldi october receive approval fixeddose combination ledipasvir sofosbuvir know commercially harvoni june receive approval fix dose combination sofosbuvir velpatasvir know commercially epclusa receive number contractual intellectual property claim sofosbuvir carefully consider claim prior follow acquisition believe merit predict ultimate outcome claim range loss state patent patent application claim sofosbuvir sovaldi chemical entity metabolite fixeddose combination ledipasvir sofosbuvir harvoni sofosbuvir velpatasvir epclusa party obtain right patent allegedly prevent attempt prevent commercialize epclusa harvoni sovaldi example aware patent patent application own party future allege party cover use epclusa harvoni sovaldi predict ultimate outcome intellectual property claim relate epclusa harvoni sovaldi spend continue spend significant resource defend claim party successfully obtain valid enforceable patent successfully prove infringement patent epclusa harvoni andor sovaldi prevent sell product able obtain license patent license available commercially reasonable term interference proceeding litigation idenix pharmaceuticals inc idenix universita degli studi di cagliari udsg centre national de la recherche scientifique luniversite montpellier ii february receive notice patent trademark office uspto declare interference idenix interference patent patent idenixs pende patent application determine invent certain nucleoside compound january uspto patent trial appeal board ptab determine pharmasset idenix invent compound idenix appeal ptab decision district court district delaware stayed appeal pende outcome appeal interference involve idenixs patent patent describe december receive request uspto declare interference second idenix interference pende patent application idenixs patent patent patent include claim direct method treat hcv nucleoside compound march ptab determine pharmasset idenix invent claim method treat hcv idenix appeal decision district court district delaware court appeal federal circuit cafc cafc hear oral argument september awaiting decision file motion dismiss appeal delaware court stay appeal relate second idenix interference believe idenix claim involve second idenix interference similar foreign patent claim compound metabolite use thereof invalid result file impeachment action federal court canada invalidate idenix canadian patent patent canadian patent correspond patent idenix assert commercialization sovaldi canada infringe patent canadian patent correspond patent invalid november canadian court hold idenixs patent invalid patent valid idenix appeal decision canadian federal court appeal november appeal hearing hold january await decision file similar legal action norway oslo district court seek invalidate idenixs norwegian patent correspond patent september idenix file invalidation action norwegian proceeding norwegian patent correspond patent march norwegian court find claim idenix norwegian patent invalid upheld validity claim patent idenix appeal decision norwegian court appeal april court appeal issue decision invalidate idenix patent uphold patent idenix file appeal january file legal action federal court australia seek invalidate idenixs australian patent correspond patent april idenix assert commercialization sovaldi australia infringe australian patent correspond patent march australian court revoke idenixs australian patent idenix appeal decision appeal hearing hold november await decision march european patent office epo grant idenix european patent patent correspond patent day patent grant file opposition epo seek revoke patent opposition hearing hold february epo rule favor revoke patent idenix appeal march idenix initiate infringement proceeding united kingdom uk germany france allege commercialization sovaldi infringe uk german french counterpart patent trial hold uk october december high court justice england wale uk court invalidate challenge claim patent multiple ground idenix appeal november appeal court affirm uk court decision invalidate idenixs patent march german court dsseldorf determine idenix patent highly likely invalid stay infringement proceeding pende outcome opposition hearing hold epo february idenix appeal decision german court staying proceeding idenixs request french proceeding stay idenix award patent correspond patent japan china december idenix universita degli studi di cagliari udsg centre national de la recherche scientifique luniversit montpellier ii sue district court district delaware allege commercialization sofosbuvir infringe patent interference exist patent patent december idenix udsg sue district court district massachusetts allege commercialization sofosbuvir infringe patent nos patent patent june court transfer massachusetts litigation district court district delaware idenix acquire merck co inc merck august prior trial december idenix commit covenant sue respect claim arise patent relate sofosbuvir withdraw patent trial addition idenix decline litigate patent infringement action trial light appeal currently pende cafc january district court stay idenixs infringement claim patent pende outcome appeal interference decision patent describe jury trial hold december remain patent december jury find willfully infringe assert claim patent award idenix billion past damage party file posttrial motion briefing quarter expect judge rule fourth quarter judge issue ruling case cafc predict certainty ultimate outcome litigation believe jury verdict error believe error court respect certain ruling trial confident merit case vigorously pursue position posttrial motion appeal expect argument forthcome posttrial motion appeal focus argument judge jury properly construe gilead infringe claim patent ii patent invalid failure properly describe claim invention iii patent invalid enable skill art practice claim invention assess accrue liability litigation consolidate financial statement consider factor include legal factual circumstance case uspto invalidation idenix patent similar patent dispute case jury verdict court posttrial order current status proceeding applicable law view legal counsel likelihood jurys verdict upheld appeal result review determined accordance applicable accounting standard probable incur loss result litigation record liability matter believe loss probable reasonably possible loss occur jurys verdict upheld appeal loss zero jurys verdict upheld appeal estimate potential loss december include billion determined jury represent adjust revenue sofosbuvir contain product launch august ii approximately million represent adjust revenue sofosbuvir contain product september december iii prejudgment interest iv enhance damage time sum ii result jurys find willfulness v attorney fee estimate range possible loss december zero billion sum exclude immaterial relate prejudgment sale interest january ii go forward royalty assess court estimate time high result jury find willfulness payable base adjusted revenue sofosbuvircontaine product period january expiry idenix patent expect judge rule go forward royalty enhance damage course decide posttrial motion time determine judge case court determination enhance damage appeal jurys verdict upheld appeal require pay material time magnitude payment material adverse impact result operation stock price litigation merck august merck contact request pay royalty sale sofosbuvir obtain license patent patent patent patent coown ionis pharmaceuticals inc patent cover compound include relate sofosbuvir file lawsuit august district court northern district california seek declaratory judgment merck patent invalid infringe patent prosecution merck amend patent application attempt cover compound relate sofosbuvir initially march jury determine establish merck patent invalid lack write description lack enablement award merck million damage june court rule gilead favor defense unclean hand determine merck recover damage patent judge determined merck require pay attorney fee exceptional nature case fee owe merck determine court merck file notice appeal court appeal federal circuit court decision defense unclean hand appeal issue relate invalidity merck patent decision defense unclean hand reverse appeal merck patent uphold require pay damage royalty sale sofosbuvircontaine product follow appeal event judge indicate determine royalty necessary conclusion appeal case litigation university minnesota university minnesota university obtain patent patent purport broadly cover nucleosides antiviral anticancer activity august university file lawsuit district court district minnesota allege commercialization sofosbuvircontaine product infringe patent believe patent invalid infringe continue commercialization sofosbuvir european patent claim february party file opposition epo request revocation grant european patent cover sofosbuvir expire october epo uphold validity certain claim sofosbuvir patent anticipate challenger appeal decision favor patent appeal process year january party file opposition epo request revocation grant european patent cover taf expire march party file opposition epo request revocation grant european patent cover cobicistat expire confident strength patent predict ultimate outcome opposition unsuccessful defend opposition patent claim narrowed revoke patent protection sofosbuvir taf cobicistat europe substantially shorten eliminate entirely patent revoke european patent grant covering compound exclusivity base entirely regulatory exclusivity grant european medicine agency sovaldi grant regulatory exclusivity prevent generic sofosbuvir enter european union year follow approval sovaldi january lose exclusivity sovaldi prior expect revenue result operation negatively impact year include succeed year exclusivity lose cause stock price decline litigation generic manufacturer approval process product fda grant new chemical entity nce exclusivity period manufacturer application approval generic version product approve generic manufacturer challenge patent protect product grant nce exclusivity year prior end nce exclusivity period generic manufacturer seek continue seek fda approval similar identical drug abbreviate new drug application anda application form typically manufacturer seek approval generic drug sale generic version product early patent expiration significant negative effect revenue result operation seek approval generic version product nce status generic company submit anda fda year brand product approval sofosbuvir date fall december consequently possible generic file anda sovaldi december current legal proceeding significance generic manufacturer include hiv product november december august receive notice teva submit abbreviate new drug submission and canadian minister health request permission manufacture market generic version truvada atripla viread notice teva allege patent associate truvada atripla viread invalid unenforceable andor infringe tevas manufacture use sale generic version product file lawsuit teva federal court canada seek order prohibition approval application december court issue order prohibit canadian minister health approving tevas generic version viread truvada atripla product expiry patent july teva appeal decision court decision rule validity patent accordingly issue appeal canadian minister health prohibit approve tevas product november teva enter settlement agreement resolve ongoing contested proceeding concern tevas ands generic version truvada atripla viread gilead patent associate truvada atripla viread june receive notice apotex inc apotex submit and canadian minister health request permission manufacture market generic version truvada separate and request permission manufacture market generic version viread notice apotex allege patent associate truvada patent associate viread invalid unenforceable andor infringe apotexs manufacture use sale generic version truvada viread august file lawsuit apotex federal court canada seek order prohibition approval and hear case hold april july court issue order prohibit canadian minister health approving apotexs generic version viread product expiry patent july court decline prohibit approval apotexs generic version truvada product court decision rule validity patent launch apotexs generic version truvada product risk infringement patent include patent unable assert present lawsuit liability damage apotex appeal court decision february receive notice mylan pharmaceuticals inc mylan submit anda fda request permission manufacture market generic version tybost cobicistat notice mylan allege patent cover cobicistat invalid obvious mylan generic product infringe invalid claim march file lawsuit mylan district court district delaware district court northern district west virginia january receive letter mylan notify submit duplicate anda fda product currently evaluate mylan letter trial delaware schedule january patent suit cover tybost list orange book stribild genvoya letairis february receive notice watson laboratories inc watson submit anda fda request permission manufacture market generic version letairis notice watson allege patent associate ambrisentan tablet invalid unenforceable andor infringe watson manufacture use sale generic version letairis april file lawsuit watson district court district new jersey infringement patent january reach agreement watson settle litigation june receive notice sigmapharm laboratory llc sigmapharm submit anda fda request permission manufacture market generic version letairis notice sigmapharm allege patent associate ambrisentan tablet invalid unenforceable andor infringe sigmapharm manufacture use sale generic version letairis june file lawsuit sigmapharm district court district new jersey infringement patent date trial sigmapharm set estimate occur second quarter predict ultimate outcome action spend significant resource enforce defend patent unsuccessful lawsuit claim patent narrow invalidated patent protection product substantially shorten patent cover product invalidate fda canadian minister health approve request manufacture generic version products united states canada respectively prior expiration date patent sale generic version product early patent expiration significant negative effect revenue result operation taf litigation january aids healthcare foundation inc ahf file complaint district court northern district california gilead japan tobacco inc japan tobacco international usa jt emory university emory april ahf amend complaint add janssen johnson johnson inc jj defendants ahf claim patent nos invalid addition ahf claim gilead independently jt akros janssen jj violate federal state antitrust unfair competition law market sale taf offer taf fixeddose combination product elvitegravir cobicistat emtricitabine genvoya fixeddose combination product elvitegravir rilpivirine odefsey fixeddose combination product elvitegravir descovy ahf seek declaratory judgment invalidity patent monetary damage jt janssen jj file motion dismiss ahfs claim ahf oppose june hearing hold motion dismiss july judge grant defendant motion dismiss ahfs claim ahf appeal court decision dismiss challenge validity taf patents department justice investigation june receive subpoena attorney office northern district california request document relate manufacture relate quality distribution practice complera atripla truvada viread emtriva hepsera letairis cooperate government inquiry april united states department justice inform follow investigation decline intervene false claim act lawsuit file employee april employee serve amend complaint january federal district court issue order grant entirety prejudice motion dismiss amend complaint february plaintiff file second amend complaint june federal district court issue order grant motion dismiss second amend complaint july plaintiff file notice appeal court appeal ninth circuit february receive subpoena attorney office district massachusetts request document relate support c organization provide financial assistance patient hcv product document concern provision financial assistance patient company disclose similar inquiry cooperate inquiry matter party legal action arise ordinary course business believe legal action material adverse impact consolidate business financial position result operation commitment normal course business enter firm purchase commitment primarily relate active pharmaceutical ingredient certain inventory relate item december commitment year approximately billion million million million million amount relate active pharmaceutical ingredient represent minimum purchase commitment actual payment purchase relate active pharmaceutical ingredient billion billion billion stockholder equity stock repurchase programs february board director authorize billion stock repurchase program program purchase program open market privately negotiate transaction program commence billion stock repurchase program authorize board director january complete second quarter billion stock repurchase program authorize board director program complete quarter billion repurchase program authorize board director january program complete december remain authorize repurchase program billion february enter accelerate stock repurchase program asr repurchase billion common stock program upfront payment billion receive million share common stock million share represent approximately total share calculate base common stock closing price share date enter asr april asr settle receive additional million share common stock base average price common stock asr purchase period predetermine discount result average purchase price common stock asr share account asr separate transaction share common stock acquire treasury stock transaction record transaction date b forward contract index common stock upfront payment billion account reduction stockholder equity consolidated balance sheet period payment asr meet applicable criterion equity classification account derivative instrument share receive asr retire period receive follow table summarize stock repurchase abovedescribe program millions share datum year end december share repurchase retire average price share note include million share repurchase billion program million share repurchase billion program include million share repurchase billion program million share repurchase billion program include million share repurchase billion program million share repurchase billion program addition repurchase stock repurchase program repurchase share common stock withhold employee restrict stock award satisfy applicable tax withholding obligation immaterial exclude table use par value method accounting stock repurchase par value method common stock charge par value share involve excess cost share acquire par value allocate additional paidin capital apic base estimate average sale price issue share excess amount charge retain earning follow table summarize reduction common stock apic charge retain earning result stock repurchase millions year end december reduction common stock apic charge retain earning dividend follow table summarize cash dividend declare common stock million share datum dividend share dividend share quarter second quarter quarter fourth quarter total restrict stock performancebase stock unit dividend equivalent right entitle holder dividend equivalent pay vest share underlie unit february announce board director declare quarterly cash dividend share common stock payment date march stockholders record close business march future dividend subject declaration board director prefer stock million share authorize preferred stock issuable series board authorize determine designation power preference right series prefer stock outstanding december accumulate comprehensive income follow table summarize change aoci component net tax million unrealize gain loss unrealize gain foreign currency availableforsale loss cash translation security flow hedge total balance december comprehensive income loss reclassification amount reclassify accumulated comprehensive income net current period comprehensive income loss balance december comprehensive income reclassification amount reclassify accumulated comprehensive income net current period comprehensive income balance december amount reclassify gain loss cash flow hedge record product sale consolidate statement income note derivative financial instrument additional information amount reclassify gain loss availableforsale security record income expense net consolidated statement income employee benefit utilize share base compensation form type equitybase award include restrict stock unit rsus performancebase restrict stock unit psus stock option compensation expense recognize consolidated statement income base estimate fair value award grant date estimate fair value rsus base closing price common stock psus estimate fair value base monte carlo valuation methodology stock price date grant stock option award estimate fair value base blackschole option valuation model equity incentive plan stockholder approve adopt gilead sciences inc equity incentive plan amend plan plan broad base incentive plan provide grant equitybase award include stock option restrict stock unit restrict stock award performance award employee director consultant plan authorize issuance total million share common stock december total million share remain available future grant plan stock option plan provide option grant designate nonqualifie incentive stock option prior january grant nonqualified incentive stock option stock option grant january nonqualified stock option plan employee stock option grant prior generally vest year stock option grant start generally vest year option exercisable period exceed contractual term year date stock option issue grant price fair market value common stock grant date stock option exercise settle common stock plan previously authorize available pool share follow table summarize activity relate information stock option plan option grant present table exercise price fair value underlie common stock grant date weight weightedaverage average remain share exercise price contractual term aggregate intrinsic thousand dollar year value millions outstanding december grant forfeit expired exercise outstanding december exercisable december expect vest net estimate forfeiture december aggregate intrinsic value represent value close stock price trading day year excess weightedaverage exercise price multiply number option outstanding exercisable total intrinsic value option exercise million billion billion weightedaverage grant date fair value stock option grant share share share december million unrecognized compensation cost relate stock option expect recognize estimate weightedaverage period year performancebase restrict stock unit plan grant psus vest achievement specify market performance goal include achieve total shareholder return compare predetermine peer group achieve revenue target actual number common share ultimately issue calculated multiplying number psus payout percentage range award generally vest committee subcommittee board determine specify market performance goal achieve fair value psu estimate date grant performance objective define grant depend term award fair value date grant determine base monte carlo valuation methodology closing stock price date grant addition grant psus certain employee plan vest award subject achievement specify individual performance goal typically year period fair value award equal closing price common stock grant date follow table summarize activity relate information psus weight average grantdate fair value share share thousand dollar outstanding december grant vest forfeited outstanding december note weightedaverage grantdate fair value share exclude share relate grant currently grantdate fair value performance objective define weightedaverage grant date fair value psus grant share share share total grant date fair value vest psus million million million total fair value respective vest date million million million recognize stockbased compensation expense million million million related psus december million unrecognized compensation cost relate psus expect recognize estimate weightedaverage period year restrict stock unit grant timebase rsus certain employee annual employee equity compensation review program new hire employee nonemployee members board rsus share awards entitle holder receive freely tradable share common stock vest rsus vest year date grant fair value rsu equal closing price common stock grant date follow table summarize rsu activity relate information weight average grantdate fair value share share thousand dollar outstanding december grant vest forfeited outstanding december weightedaverage grant date fair value rsus grant share share share total grant date fair value vest rsus million million million total fair value respective vest date million million million december million unrecognized compensation cost relate unvested rsus expect recognize weightedaverage period year employee stock purchase plan employee stock purchase plan international employee stock purchase plan amend espp employee purchase share common stock base percentage compensation subject certain limit purchase price share equal low fair market value common stock offering date purchase date prior espp offer twoyear lookback feature automatic reset feature provide offer period reset new lowerpriced offering offer price new offering period current offering period begin quarter lookback feature espp offering period sixmonth espp purchase settle common stock espps previously authorize available pool share million share issue espp million total million share common stock authorize issuance espp million share available issuance espp december december million unrecognized compensation cost relate espp expect recognize estimate weightedaverage period year stockbase compensation follow table summarize stockbase compensation expense include consolidated statement income million year end december cost good sell research development expense sell general administrative expense stockbase compensation expense include total cost expense income tax effect stockbase compensation expense net tax capitalize stockbased compensation cost inventory total million million million capitalize stockbased compensation cost remain inventory million december million december million december stockbase compensation recognize expense requisite service period consolidate statement income straightline expense attribution approach reduce estimate forfeiture estimate forfeiture base historical experience valuation assumption fair value option grant plan purchase espp estimate grant purchase date blackschole option valuation model blackschole option valuation model develop use estimate fair value trade option vest restriction fully transferable addition option valuation model require input highly subjective assumption include expect stock price volatility expect award life follow assumption calculate estimate fair value award year end december expect volatility stock option espp expect term year stock option espp riskfree interest rate stock option espp expect dividend yield fair value stock option grant calculate single option approach use blend historical volatility imply volatility trade option common stock determine expect volatility expect term stockbase award represent weightedaverage period award expect remain outstanding estimate weightedaverage expect term base historical cancellation historical exercise datum relate stock option contractual term vest term award riskfree interest rate base observe interest rate appropriate term stockbase award dividend yield base history expectation dividend payout defer compensation maintain retirement saving plan eligible employee defer compensation income tax purpose section k internal revenue code gilead science k plan certain foreign subsidiary maintain define benefit plan require local regulatory requirement total matching contribution expense gilead science k plan define benefit plan million million million maintain deferred compensation plan director key employee defer compensation amount defer participant deposit rabbi trust total asset liability associate defer compensation plan million december million december net income share attributable gilead common stockholder basic net income share attributable gilead common stockholder calculate base weightedaverage number share common stock outstanding period dilute net income share attributable gilead common stockholder calculate base weightedaverage number share common stock outstanding dilutive security outstanding period potential dilutive share common stock result assume exercise outstanding stock option equivalent assume conversion outstanding convertible note assume exercise warrant determine treasury stock method march exercise option elect cash settlement conversion spread remain convertible note prior cash settlement election common stock result assume settlement conversion spread convertible note dilutive effect average market price common stock period exceed conversion price convertible note result include dilutive impact net income share calculation additionally quarter warrant expire exercise option settle warrant cash prior settlement common stock result assume settlement warrant dilutive effect average market price common stock period exceed warrant exercise price result include dilutive impact net income share calculation note debt credit facility additional information asr reflect repurchase common stock receipt share forward contract index common stock exclude forward contract computation dilute net income share attributable gilead common stockholder effect antidilutive exclude stock option purchase approximately million million million weightedaverage share common stock outstanding respectively computation dilute net income share attributable gilead common stockholder effect antidilutive follow table show calculation basic diluted net income share attributable gilead common stockholder million share amount year end december net income attributable gilead share share calculation basic effect dilutive security stock option equivalent conversion spread relate convertible note warrant relate convertible note share share calculation dilute net income share attributable gilead common stockholder basic net income share attributable gilead common stockholder dilute segment information operating segment primarily focus discovery development commercialization innovative medicine area unmet medical need result operation report consolidated basis consistent internal management reporting review chief operating decision maker chief executive officer enterprisewide disclosure product sale revenue longlive assets geographic area revenue major customer present product sale product sale consist follow millions year end december antiviral product harvoni sovaldi truvada atripla stribild epclusa genvoya compleraeviplera viread odefsey descovy antiviral total antiviral product product letairis ranexa ambisome zydelig product total product sale revenue geographic region follow table summarize total revenue external customer collaboration partner geographic region million product sale productrelate contract revenue attribute region base shipto location royalty nonproduct relate contract revenue attribute region base location collaboration partner year end december revenues united states europe japan countries total revenue longlive asset net book value property plant equipment office computer equipment united states billion december billion december billion december corresponding international location million december million december million december individual international location account percent total balance revenue major customer follow table summarize revenue customer individually account total revenue percentage total revenue year end december mckesson corp amerisourcebergen corp cardinal health inc income taxis income provision income taxis consist follow millions year end december domestic foreign total income provision income taxis provision income taxis consist follow millions year end december federal current deferred state current defer foreign current defer provision income taxis cumulative unremitted foreign earning consider indefinitely reinveste foreign subsidiary taxis provide approximately billion december billion december residual tax liability amount remit approximately billion december billion december reconciliation federal statutory tax rate apply income taxis effective tax rate summarize follow year end december federal statutory rate state taxis net federal benefit foreign earning different rate research credit net unbenefitted stock compensation effective tax rate defer income taxis reflect net tax effect temporary difference carry amount asset liability financial reporting purpose amount income tax purpose significant component defer tax asset liability follow million december defer tax asset net operating loss carryforward stockbase compensation reserve accrual currently deductible defer revenue depreciation relate research credit carryforward net total defer tax asset valuation allowance valuation allowance total defer tax asset defer tax liability intangible unremitted foreign earning total defer tax liability net defer tax asset valuation allowance million december million december million december increase valuation allowance december december primarily write iprd value momelotinib december federal net operating loss carryforward approximately million federal net operating loss carryforward start expire utilize federal tax credit carryforward approximately million start expire utilize addition state net operating loss tax credit carryforward approximately million million respectively state net operating loss tax credit carryforward start expire utilize utilization net operating loss tax credit subject annual limitation ownership change limitation provide internal revenue code amend similar state provision annual limitation result expiration net operating loss credit utilization file federal state foreign income tax return unite states jurisdiction abroad federal income tax purpose statute limitation open onwards certain acquire entity statute limitation open year inception utilization net operating loss credit carry prior year california income tax purpose statute limitation open onwards income tax return subject audit federal state foreign tax authority currently examination irs tax year state foreign jurisdiction differ interpretation tax law regulation result significant dispute arise tax authority involve issue time deduction allocation income tax jurisdiction periodically evaluate exposure associate tax filing position total federal state foreign unrecognized tax benefit billion december billion december total unrecognized tax benefit billion billion december respectively recognize reduce effective tax rate period recognition continue classify interest penalty relate unrecognized tax benefit income tax provision consolidate statement income accrue interest penalty relate unrecognized tax benefit million december million december december believe unrecognized tax benefit significantly change month high degree uncertainly time clarification irs tax authority uncertain tax position unable reasonably estimate period cash settlement respective tax authority follow rollforward total gross unrecognized tax benefit liability millions december balance beginning period tax position relate current year addition reduction tax position relate prior year addition reduction settlement lapse statute limitation balance end period select quarterly financial information unaudite follow amount million share amount st quarter nd quarter rd quarter th quarter total revenue gross profit product sale net income net income attributable gilead net income share attributable gilead common stockholdersbasic net income share attributable gilead common stockholdersdilute total revenue gross profit product sale net income net income attributable gilead net income share attributable gilead common stockholdersbasic net income share attributable gilead common stockholdersdilute gilead sciences inc schedule ii valuation qualifying account million balance begin additionscharged balance end period expense deduction period year end december account receivable allowance sale return allowance valuation allowance defer tax asset year end december account receivable allowance sale return allowance valuation allowance defer tax asset year end december account receivable allowance sale return allowance valuation allowance defer tax asset note allowance doubtful account cash discount chargeback valuation allowance defer tax asset include million million million december respectively relate acquisition item change disagreement accountant account financial disclosure applicable item control procedure evaluation disclosure control procedure evaluation december carry supervision participation management include chief executive officer chief financial officer effectiveness disclosure control procedure define rule ae securities exchange act amended exchange act control procedure company design ensure information require disclose company report file submit exchange act record process summarize report time period specify security exchange commission rule form information accumulate communicate company management include chief executive officer chief financial officer appropriate allow timely decision require disclosure base evaluation chief executive officer chief financial officer conclude disclosure control procedure effective december b management report internal control financial reporting management responsible establish maintain adequate internal control financial reporting term define rule af exchange act internal control system design provide reasonable assurance preparation fair presentation financial statement external purpose accordance generally accept accounting principle internal control system matter design inherent limitation provide reasonable assurance objective internal control system meet supervision participation management include chief executive officer chief financial officer conduct evaluation effectiveness internal control financial reporting base criterion establish committee sponsor organization treadway commission coso internal controlintegrate framework base evaluation conclude internal control financial reporting effective december independent register public accounting firm ernst young llp audit consolidated financial statement include item annual report issue report internal control financial reporting december report audit internal control financial reporting appear c change internal control financial reporting management include chief executive officer chief financial officer evaluate change internal control financial reporting occur quarter end december conclude change quarter materially affect reasonably likely materially affect internal control financial reporting report independent register public accounting firm board director stockholder gilead sciences inc audit gilead sciences inc internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission framework coso criterion gilead sciences incs management responsible maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include accompany management report internal control financial reporting responsibility express opinion company internal control financial reporting base audit conduct audit accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance effective internal control financial reporting maintain material respect audit include obtain understand internal control financial reporting assess risk material weakness exist test evaluate design operating effectiveness internal control base assess risk perform procedure consider necessary circumstance believe audit provide reasonable basis opinion company internal control financial reporting process design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle companys internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition asset company provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate opinion gilead sciences inc maintain material respect effective internal control financial reporting december base coso criterion audit accordance standard public company accounting oversight board united states consolidated financial statement gilead sciences inc report date february express unqualified opinion thereon ernst young llp redwood city california february item b information applicable iii item director executive officer corporate governance information require item concern director executive officer incorporate reference section definitive proxy statement file securities exchange commission pursuant regulation connection annual meeting stockholder proxy statement heading nominee board committee meeting executive officer section beneficial ownership reporting compliance write code ethic apply director employee include executive officer include limitation principal executive officer principal financial officer principal accounting officer controller person perform similar function code ethic available website httpwwwgileadcom investor section corporate governance change waiver code ethic disclose website intend satisfy disclosure requirement item form k amendment waiver provision code ethic disclose information website item executive compensation information require item incorporate reference section proxy statement heading executive compensation compensation committee interlock insider participation compensation committee report compensation nonemployee board member item security ownership certain beneficial owner management relate stockholder matter information require item incorporate reference section proxy statement heading security ownership certain beneficial owner management security authorize issuance equity compensation plan item certain relationship relate transaction director independence information require item incorporate reference section proxy statement heading nominee certain relationship relate party transaction item principal accountant fee service information require item incorporate reference section proxy statement head principal accountant fee service iv item